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1. INTRODUCTION  
 
Breast cancer is the most common malignant tumor in women. Previously, breast 
cancer was considered a loco-regional disease (Halsted theory) and the standard procedure for 
treatment was radical and supra-radical mastectomy. As a consequence, internal mammary 
(IM) lymph node dissection was part of the standard surgical treatment in some centers in the 
1950s and 1960s. This radical surgical procedure was abandoned in the 1970s because patient 
outcome studies showed that radical dissection did not improve survival [1]. 
The paradigm shift in breast cancer surgery occurred in the 1980s with the spreading 
of the biological approach (Fisher theory) which stated that breast cancer is a systemic disease 
form the onset, therefore the radicality of the local treatment has not impact on the overall 
survival rate. Bernard Fisher and Umberto Veronesi found that conservative surgery 
complemented by radiotherapy (RT) resulted in a long-term outcome similar to mastectomy 
for both local recurrence and survival. This process was supported by the introduction and 
development of breast screening programmes, allowing the detection of ever smaller size 
tumors.  
Currently, the majority of cases of breast cancer are detected at an early stage, with 
relatively small size and limited or no lymph node involvement. As a result of screening 
programmes, the average size of tumors and consequently the proportion of cases with lymph 
node involvement, especially those with massive lymph node involvement have decreased 
significantly [2, 3], more tumors are detected in an in situ, non-invasive state. This tendency 
has impacted on the surgical approach as the proportion of conservative operations in contrast 
to mastectomy has increased. From the mid-1990s, sentinel lymph node biopsy (SLNB) has 
become a widely used procedure, based on the assumption that not all axillary lymph nodes 
are equally likely to be involved, but there is one or there are some which have direct 
connection via afferent lymphatic vessels with the location of the primary tumor, and these 
are most probably affected by the first developing regional metastases.  
The relevance of this theory was supported by many studies [4]. From the previous 
fundamental statement, the following one can also be deducted: if the sentinel lymph nodes 
(SLNs) are not involved, the metastasis free status of non-sentinel lymph nodes (NSLNs) is 
highly probable. The basic procedure for visualizing SLNs is lymphoscintigraphy, a 
procedure which can show the presence of not only axillary but also internal mammary 
sentinel lymph nodes (IM-SLNs). Biopsy of these latter has not become a routine surgical 
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procedure. The same reasoning as the one leading to the introduction of SLNB has lead to 
questioning the need to perform axillary lymph node dissection (ALND) in all cases with 
SLN involvement.  
Generally speaking, surgery of breast cancer has gradually become more and more 
conservative both at the primary site and the regional lymph nodes. 
Single duct nipple discharge , especially when the fluid is blood stained, is a typical 
but not general and not specific initial symptom of breast cancer. This symptom may also be 
associated with central, subareolar intraductal papillomas or other papillary lesions [5]. 
The majority of solitary papillomas are benign, although they can be associated with 
cytological or structural atypia, in-situ or invasive malignancy [6]. Most intraductal 
papillomas are small (less than 5 mm in diameter), however papillomas as large as 10 cm 
have been reported [7]. Their standard diagnostic work-up includes mammography and 
ductography. 
Most women presenting with nipple discharge have normal mammograms, but 
ductography may visualize intraductal lesions [8]. In addition, some investigators perform 
ultrasonography of the retro-areolar region to visualize enlarged ducts. Recently, magnetic 
resonance imaging (MRI) has been reported as a useful adjunct to ductography in the 
detection of intraductal papillomas, as well as malignancies with a significant intraductal 
component [9]. Ductoscopy is a new technical improvement allowing intraductal biopsy and 
therefore its introduction may be of help in the evaluation of intraductal lesions [10]. 
Ultrasound (US) guided vacuum assisted biopsy or removal of the lesion is another diagnostic 
option [11]. An alternative diagnostic procedure is the histological verification of intraductal 
lesions following selective ductectomy (SD), a conservative surgical excisional procedure 
aiming at the removal of the discharging duct with a minimal rim of periductal breast tissue.  
The surgical treatment of breast cancer has substantially changed during the last 
decades. Lymph node status was the most important single prognostic factor of the disease 
and lymph nodes were removed for diagnostic (prognostic) and therapeutic purposes. SLNB 
has widely become the standard surgical procedure for axillary staging of clinically node-
negative patients, and preoperative clinical assessment has often been supplemented with 
axillary ultrasound (AXUS) and fine needle aspiration cytology (FNAC) or core needle 
biopsy (CNB) of suspicious nodes. If the SLNs contain no metastasis, no further axillary 
treatment is envisaged, and the omission of ALND in patients with negative SLNs has proved 
to be safe [12-16]. On the other extreme, clinically detected metastases in the axillary lymph 
nodes still require surgery, generally in the form of ALND.  
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The two main nodal regions of the breast are the axillary and the parasternal or internal 
mammary (IM), the latter consisting of approximately 8 lymph nodes. Although studies of 
lymphatic drainage patterns report internal mammary chain (IMC) involvement in 13–35%, 
the value of an SLN procedure for the IMC is still controversial [17-21]. Most authors do not 
perform IM-SLNB, because the clinical importance and therapeutical implications of IM-SLN 
metastases are unclear. Tumor location within the breast may influence the prevalence of IM 
nodal metastases. Medial tumors may have IM drainage somewhat more often than breast 
tumors at other locations, but tumor location alone has not been found to be a good predictor 
of IM-SLN involvement [22]. Whether the site of the primary breast tumor should be 
considered when deciding about IM-SLNB can also be a matter of debate. In addition to the 
axillary lymph node status, the IM lymph node status also provides prognostic information in 
breast cancer patients [23]. If positive, prognosis is less favourable. The worse prognosis can 
be expected in patients with involvement of both nodal regions, whereas patients with 
involvement of either region alone seem to have similar prognosis [22]. 
Although a positive SLN lead to an ALND in most patients, evidence suggests that a 
majority of SLN-positive patients do not have further lymph node involvement [24, 25]. It is 
even evident that further lymph node involvement does not manifest itself in recurrent disease 
in the majority of patients, provided adjuvant therapies are used according to current 
standards [26-29]. Therefore, omission of ALND has been a trend in at least a subset of SLN-
positive patients for several years, even before the publication of the results of the American 
College of Surgeons Oncology Group (ACOSOG) trial Z-0011 [30-32]. Recent guideline 
recommendations acknowledge that limited SLN involvement does not necessarily require 
ALND in all patients [33, 34], and suggest that there is not need for ALND if the SLN 
involvement is at most micrometastatic [33, 34].  
In contrast, the largest retrospective series of micrometastatic SLN patients suggest 
that there is a small minority of patients with SLN micrometastasis who have a significant risk 
and incidence of non-SLN (NSLN) involvement [35]. Nomograms devised for the prediction 
of NSLN metastasis in patients with micrometastatic SLNs suggest over 30% or close to 50% 
risk at their extremes [36-38]. On the basis of multivariate models, several factors affect the 
risk of NSLN involvement beside the size of the SLN metastasis [35-39]. Therefore, the 
omission of ALND in all micrometastatic SLN patients might be negligent. This is why 
follow-up data of patients with limited SLN involvement but no ALND is still important [34].  
Compared to female breast cancer male breast cancer (MBC) is a rare disease 
representing less than 1 % of all malignancies in men and only 1 % of all incident breast 
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cancers [40-43]. Due to the rarity of MBC, there is a lack of prospective clinical trials to 
deﬁne optimum treatment. Because of the low number of affected patients, treatment for 
MBC has been extrapolated from treatment protocols relating to breast cancer occurring in 
women. Mastectomy with axillary dissection is still the most commonly recommended 
procedure for MBC. There have been several reports on the use of SLNB in men, although the 
numbers of patients and length of follow-up have been limited [44-49]. 
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2. AIMS  
 
1. To analyze the role of selective ductectomy for the diagnosis and treatment of 
intraductal lesions presenting with single or rarely dual duct discharge and ductography 
suggestive of intraductal (papillary) lesions. To investigate the incidence of association of 
neoplastic proliferations or malignancy in this group.  
2. To investigate in what percentage lymphoscintigraphy visualized IM-SLNs during the 
axillary SLNB (A-SLNB) operations performed in patients with invasive, clinically node-
negative breast cancer. To analyze in what proportion the IM-SLNB was successful in these 
patients, what was the rate of metastatic IM-SLNs and what were the factors influencing the 
presence of metastatic involvement. To assess to what extent the IM-SLN involvement has 
lead to a change in treatment. 
3. To investigate the role of SLNB in MBC. 
4. To asses the impact of omitting ALND in breast cancer patients with low volume SLN 
metastasis on locoregional recurrence and disease-free and overall survival.  
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3.  PATIENTS AND METHODS 
 
3.1 Selective ductectomy for the diagnosis and treatment of intraductal papillary lesions 
presenting with single duct discharge. 
 
Files of patients presenting with single (or rarely dual) duct discharge at the 
Department of Surgery or Breast Diagnostics of Bács-Kiskun County Teaching Hospital were 
retrospectively reviewed. Patients were evaluated and treated within a multidisciplinary 
setting, and whenever an intraductal obliteration (partial or complete) was evidenced by 
imaging studies, SD was considered as a diagnostic and therapeutic intervention. Only patient 
undergoing SD were further evaluated in this retrospective analysis. Bilateral two-view-
mammography (craniocaudal – CC, and mediolateral oblique - MLO), ultrasonography and 
ductography were performed in all patients. For ductography, 2 ml contrast media (Ultravist 
iopromide, Bayer, Berlin, Germany) was injected through a 27 gauge cannula (Anel, Luer-
Lock, Medicor, Debrecen, Hungary) into the discharging duct, then CC and MLO views of 
the given breast were obtained. Spot compression magnification views of the area of concern 
were also analyzed. The suspicion of a papilloma was raised when a regular intraluminal 
filling defect was seen. (Fig. 1).  
Nipple discharge cytology was evaluated in all cases. Whenever a mass lesion was 
also identified by US, US-guided FNAC or CNB was also done. Biopsy of 
microcalcifications was performed under stereotactic guidance using 14-gauge needle and a 
biopsy gun. Surgical excision was recommended on the basis of suspected intraductal 
papilloma (IP). SD was performed in the following steps. At the beginning of the operation, 
the nipple was compressed in order to visualize the duct with the discharge. One ml of Patent 
blue dye (Laboratories Guerbet, Roissy, France) was injected through a 27-gauge cannula 
inserted into the pathologic duct. Following this vital labelling of the duct, an infraareolar 
incision was made and the areolar flap was raised. The pathological duct was identified and 
the dyed 3 or 4 cm long part was removed with a small rim of surrounding breast tissue. The 
specimens were oriented with a short suture at the mammillary edge and a long suture at the 
peripheral edge (Fig. 2).  
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Figure 1  
Title:Example of a typical ductogram of a patient with single duct nipple discharge 
Description:The dilated duct fills up partially, is amputated at the end and shows irregularities 
suggestive of intraluminal protrusions. 
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Figure 2  
Title: Selective ductectomy  
Description:  
A: Identification of the duct responsible for the discharge. 
B: Cannulation of the discharging duct and administration of the vital dye into the duct. 
C: Removal of the cannulated blue stained duct from an infraareolar incision. 
D: The specimens were oriented with a short suture at the mammillary edge and a long suture 
at the peripheral edge. 
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At the time of introduction of SD, a few cases were also injected intraductally with 
radiological contrast material (2 ml Ulravist) to allow radiological detection of the lesion after 
the removal of the duct. All ducts removed were sent for histological examination. Following 
fixation in 10% buffered formalin, the ducts were sliced perpendicular to their long axis from 
the central part towards the periphery, and were blocked in consecutive transsectional planes. 
The central and peripheral slices were always submitted for histological analysis, whereas the 
rest of the duct was either submitted in toto or only the slices including the grossly 
identifiable intraductal lesion were embedded in paraffin. Tissue sections were stained with 
hematoxylin and eosin (Fig. 3). 
 
 
 
Figure 3  
Title: Microscopy of two representative cases  
Description: A–D Selective ductectomy specimen with intraductal papilloma. Proximal (close 
to the nipple) (A) and distal (away from the nipple) (D) transections show a dilated duct with 
periductal fibrosis, but no intraductal proliferation. Similar findings also suggest proliferation 
free longitudinal margins. Transsections falling between the two edges showed an intraductal 
papilloma (B) without atypia (C). E-F Selective ductectomy specimen with intermediate 
grade cribriform DCIS. (Hematoxylin and eosin, A, B, D, E: ×20; C, F: ×400) 
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Results were categorized as isolated benign papilloma, papilloma associated with 
high-risk lesions such as atypical ductal type epithelial hyperplasia (ADH), lobular 
intraepithelial neoplasia (LN) or ductal carcinoma in situ (DCIS) and papilloma/atypical 
papilloma associated with invasive ductal carcinoma (IDC). Some non-papillary lesions fell 
outside of these categories and they also included malignant disease without papillary 
growths. 
 
3.2 Internal mammary sentinel lymph node biopsy in breast cancer. Is it indicated? 
 
Selective ALND based on A-SLNB results was introduced in our hospital with the 
approval of the local ethical committee. Between January 2001 and June 2012, 1542 patients 
with clinically node-negative operable primary breast cancer gave an informed consent and 
underwent SLNB. Except for pregnancy and T4 tumors, no patients were excluded. The 
preoperative diagnosis of breast cancer was established by mammography, ultrasonography 
and FNAC or CNB in all patients. Prior to surgery, AXUS was performed routinely and if 
suspicious lymph nodes were identified, FNAC was also done [50-52]. When this revealed an 
axillary lymph node metastasis, ALND was performed, whereas in case of negative cytology 
findings, A-SLNB was the staging procedure done. Our technique of SLNB involved 
intraparenchymal administration (intra- and/or peritumoral injection in 3–4 depots) of 60–90 
MBq 99mTc-labelled colloids the day before surgery: either 200–600 nm particle size 
Sentiscint (Medi-Radiopharma Kft., Érd, Hungary) or 40–80 nm particle size colloids 
Nanoalbumon (Medi-Radiopharma Kft., Érd, Hungary) or Nanocoll (Gipharma, Saluggia, 
Italy). From January 2006, we introduced superficial, periareolar injection of the radiocolloid 
according to the localization of the quadrant harboring the tumor as preferred method.  
However, in case of non-palpable tumors, the radioactive tracer was injected 
intraparenchymally, into and around the tumor, with US guidance to permit Radioguided 
Occult Lesion Localization (ROLL) [53]. Lymphoscintigraphy was generally performed 2 
hours after the administration of the radioactive tracer and was often repeated the next day, 
shortly before surgery, to check whether the highlighted lymph nodes are still there and no 
further lymph nodes have appeared. Lymphoscintigraphic images were obtained in two 
standard positions: anteroposterior and MLO. The location of the non palpable tumors, 
axillary SLNs (A-SLNs) and IM-SLNs was marked on the skin. Two ml Patent Blue dye was 
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injected intraparenchymally above the tumor after the induction of general anesthesia, 10–15 
min before the incision. Harvesting both axillary and IM-SLNs was attempted in all patients, 
as visualized on lymphoscintigraphy (Fig.4). 
 
 
 
Figure 4 
Title: The hotspot of an internal mammary sentinel lymph node (IM-SLN) on 
lymphoscintigraphy (anteroposterior view) 
Description: The IM-SLN hotspot was visualized on lymphoscintigraphy in the parasternal 
location after 2 h (a) and after 20 h (b). 
 
A-SLNB was performed before the removal of the primary carcinoma and A-SLNs 
sliced at about 2 mm intervals were subjected to imprint cytology as a means of intraoperative 
evaluation, to allow immediate ALND in patients with metastasis. The primary breast tumor 
was removed next by either breast conserving methods or by mastectomy, according to the 
tumor and patient characteristics, and the consent obtained prior to the operation. This was 
followed by IM-SLNB whenever lymphoscintigraphy highlighted IMC drainage. The IM-
SLNB technique, based on the IM-SLNB method described by van der Ent [19] can usually 
be performed using the mastectomy incision. In breast conserving operations, a small 
additional horizontal incision (2.5– 3 cm) over the desired interspace was used to sample IM-
SLNs. It is usually preferable that this incision does not cross the midline, because of 
cosmetic reasons. The pectoral major muscle was exposed for 2 to 3 cm directly over the 
desired interspace. The muscle fibers were then separated to expose the posterior intercostal 
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space. The external and internal intercostal muscles are divided transversely from the sternal 
border in a lateral direction for 3 to 4 cm. In cutting the internal intercostal muscle, particular 
care must be taken to avoid injury to the inferior parietal pleura or the internal mammary 
artery (Fig. 5). 
 
 
 
Figure 5 
Title: The technique of internal mammary sentinel lymph node (IM-SLN) biopsy: step by step 
Description:  
A: The fibers of the major pectoral muscle are separated to expose the posterior intercostal 
space. 
B: Intraoperative identification of the IM-SLN hotspot with the help of the gamma probe.  
C: The intercostal muscles were separated from the lower rib to expose the fatty tissue along 
the internal mammary vessels on the surface of the parietal pleura. 
D: The harvested IM-SLN, which is typically smaller (0.5–2 mm) than the A-SLN and rarely 
stains blue. 
In case of multiple IM hotspots on the lymphoscintigraphy, the IM lymph nodes were 
mostly retrieved through the same incision. Intraoperative identification of the A-SLNs and 
IM-SLNs was based both on blue dye mapping and gamma probe detection (C-Trak Surgical 
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Guidance System, Care Wise Medical Products Corporation, Morgan Hill, CA, USA). IM-
SLNs were not subjected to intraoperative assessment. The final pathological evaluation of all 
SLNs included formalin fixation, paraffin embedding and step sectioning at 250μm intervals 
of all slices or unsliced lymph nodes smaller than 6 mm with hematoxylin and eosin staining 
of all, and cytokeratin immunohistochemistry of several levels [54]. Metastases in the A-
SLNs discovered only in the permanent sections also generally resulted in ALND with the 
exception of a few patients. As the largest part of the study period used the 6th edition of the 
Tumor Node Metastases (TNM) classification of malignant tumors, this edition was used for 
staging purposes and the discrimination of metastases, micrometastases (MIC) and isolated 
tumor cells (ITC) [55]. Statistical analysis for the comparisons included the chi-square test for 
categorical variables and the student t test for continuous variables. The significance level was 
set at p<0.05. 
 
3.3 The role of sentinel node biopsy in male breast cancer. 
 
Twenty-ﬁve MBC patients were operated on between January 2004 and August 2013. 
The majority of patients with MBC presented with a painless, subareolar mass, often 
associated with nipple retraction or discharge [56]. At the beginning of the study period, 
mastectomy was performed with immediate ALND, without attempting SLNB. The reasoning 
behind this policy was as follows: the size of tumors in males is typically larger compared to 
females, larger tumors are more often accompanied by lymph node metastases, and there were 
insufﬁcient data on the role of SLNB in male patients. This approach was used in 9 patients. 
From 2004 the preoperative diagnosis of MBC, similarly to breast cancer in women was 
established by mammography, ultrasonography and FNAC or CNB in all patients. Prior to 
surgery, AXUS was performed routinely and if suspicious lymph nodes were identified, 
FNAC was also done [50-52]. When this revealed an A-SLN metastasis, ALND was 
performed, whereas in case of negative cytology findings, A-SLNB was the staging procedure 
done. 
AXUS routinely performed in all but a few patients at the beginning of the study 
period often helped in the demonstration of axillary lymph node involvement, as men were 
frequently diagnosed with locally advanced disease [57]. 
Survivors were asked to complete a postoperative questionnaire about the subjective 
aspects of the disease. The questions referred to previous knowledge of the existence of MBC, 
family history, main apprehension when ﬁnding out the diagnosis of breast cancer (surgery, 
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chemo-, hormonal or radiotherapy, work-related issues, sexual activity problems). The other 
set of questions referred to complaints relating to any motoric or sensorial dysfunctions on the 
operated side (arm, hand). The last set of questions was about fears of breast cancer 
recurrence. 
 
3.4 Regional disease control in selected patients with sentinel lymph node involvement and 
omission of axillary lymph node dissection. 
 
After the introduction of SLNB in August 1997 and a rather long learning period, 
early breast cancer patients with clinically node-negative disease presenting at the Bács-
Kiskun County Teaching Hospital were routinely offered SLNB from October 2000. The 
methods used were similar to those described in section 3.2. These included step sectioning of 
the sliced SLNs and cytokeratin immunohistochemistry (IHC) at multiple levels. Initially the 
SLNs were sectioned till the extinction of the tissue blocks [54], but from July 2012, after an 
initial trimming, only three layers separated by 250 microns were taken with IHC at the 
beginning and the end of the 3 steps. All patients with positive SLN findings on intraoperative 
or final histology were offered ALND. ITCs were considered negative nodal findings in this 
respect, according to the TNM recommendations, and patients with minimal nodal 
involvement belonging to this category were generally not offered ALND. Later a number of 
micrometastatic patients were also spared ALND, and a few patients with larger metastases 
also skipped completion ALND by not consenting to this operation.  
Radiotherapy  and systemic therapy was given according to national guidelines valid 
at the time of their management. Patients were followed as outpatients, and follow-up 
included six monthly mammographic and ultrasonographic assessment (including the 
examination of the axilla) in the first 3 years, and yearly imaging controls thereafter. Clinical 
controls were scheduled every 6 months in the first 5 years following breast surgery. Patients 
lost to follow-up within the first 12 months were not considered suitable for this retrospective 
analysis. The Kaplan-Meier survival estimates were used for overall, disease free and breast 
cancer specific survivals.  
Patients with SLN metastatic involvement not larger than 2 mm were analyzed for the 
risk of NSLN involvement with 3 nomograms devised for micrometastatic disease [36-38]. A 
low risk of NSLN involvement was defined as a nomogram predicted risk not greater than 
10%. Accordingly, a nomogram based risk of more than 10% was classified as high risk. For 
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the fourth predictive tool, the presence of 0 or 1 of 5 risk factors (tumor size >2cm, 
lymphovascular invasion, hormone receptor negativity, localisation in the upper outer 
quadrant, involved SLN ratio >33%) was used to define low risk patients with 
micrometastatic SLNs, as this was associated with around 10% frequency of NSLN metastasis 
in the original description [35]. Likewise, for SLNs harbouring ITC, the presence of 0 to 1 of 
3 risk factors (age younger than 40 years, tumor size >2 cm, involved SLN ratio of 100%) 
were considered to have low risk of NSLN metastasis [35]. 
Disease related events of patients classified as having high versus low risk were 
compared with the Fisher exact test, and the significance level of the two sided test was set at 
p<0.05 (VassarStats, Richard Lowry, Vassar College, Poughkeepsie, New York, USA; 
http://vassarstats.net). All patients gave an informed consent. Data were anonymized and the 
institutional data safety monitor approved their handling in such a way. The institutional 
ethical committee of Bács-Kiskun County Teaching Hospital approved this non-interventional 
retrospective analysis. 
 
4.  RESULTS 
 
4.1 Selective ductectomy for the diagnosis and treatment of intraductal papillary lesions    
presenting with single duct discharge. 
 
The retrospective review of records between January 2004 and January 2011 revealed 
100 patients with suspected intraductal papillary proliferations removed by ductectomy. The 
mean age of the patients was 52 years (range: 32– 82 years). Nipple discharge was the main 
clinical symptom in all of them. Mammography was normal in 83 cases and showed 
microcalcifications in 17 cases. US described a mass in 23 cases. A single duct discharge was 
identified in 98 cases and dual duct excretion was seen in 2 cases. The fluid discharged from 
the duct was serous in 77 cases and blood stained in 23. Cytological examination of the fluid 
discharged from the duct reported normal cells (C2) in 60 patients and showed atypical, 
probably benign cells (C3) in 40 cases [58]. CNB was obtained in 4 cases. All of them were 
B3 (breast tissue with uncertain malignant potential) lesions, corresponding to intraductal 
papilloma (n=3) and sclerosing adenosis (n=1) on final histology.  
The operations were performed under general anesthesia. The average operation time was 17 
minutes. We did not have any serious complications. Twelve patients had a mild discomfort 
in the breast wound for a day or two.  
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The histopathological findings of the surgically excised lesions revealed benign 
papilloma in 62 patients, papilloma with ADH within the papillary lesion (atypical papilloma) 
in 5, papilloma with ADH around the papillary proliferation in 4, papilloma with LN around 
the lesion in 1, an apocrine papillary lesion without myoepithelium in the central part and 
with partial lack of myoepithelium at the periphery in 1 [59], DCIS in 4 and IDC, (of which 
the name preferred by the current World Health Organization classification is invasive 
carcinoma of no special type) in 2 patients (Tables 1 and 2). 
Three of the DCIS cases and one of the IDC cases were also associated with 
papillomas (Table 1). Ductectasia was the only finding in 16 patients and other benign 
changes were seen in 5 cases. This means that out of 100 patients presenting with single duct 
discharge and ductographic changes suggestive of intraductal (papillary) proliferations, 6 
(6%) proved to have malignant disease (4 in situ and 2 invasive carcinomas). Furthermore, 14 
intraductal papillomas (18% of papillomas, 14% of all cases) were associated with neoplastic 
changes: atypical hyperplasia found in 5 and around 5 of them (Table 2), in situ carcinoma 
associated with 3 and invasive carcinoma with 1 of them (Table 1), whereas 2 malignant 
cases had no papillary proliferation at all. 
Considering the six patients with a final diagnosis of DCIS or IDC and the 10 patients 
with precursor neoplastic lesions (ADH or LN), mammography showed microcalcifications in 
two cases and ultrasonography found a mass in two (Tables 1 and 2). From the 6 malignant 
lesions, nipple discharge cytology resulted in C2 and C3 in three cases each. The initially 
performed selective ductectomy was complemented in all cases with ROLL [53] and breast 
conserving surgery plus SLNB. One of the patients needed a third operation, because of the 
positive margins of the second specimen: due to the extent of the lesion and no signs of it on 
imaging studies including breast MRI, the third operation consisted of mastectomy, followed 
by reconstruction with an implant. The SLNs were negative in all cases. Whole breast 
irradiation was delivered to 4 patients with total doses of 50 Gy. Two of them also received 
boost irradiation to the tumor bed because of close margins. Two patients were given 
chemotherapy because of grade 3 IDC and a premenopausal status. Estrogen receptor (ER) 
was positive in 5 tumors. All of these patients received hormonal therapy (HT) (Table 1).
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Table 1 Summary of patients with a malignant diagnosis 
 
Patient Age Imaging Surgery Histology/TNM Staging Size (margins)a Adjuvant 
treatment 
1 76  SD followed by reexcision IG DCIS pTis pNxM0 + intraductal papilloma 
ER: pos PgR: pos Her-2: neg 
36 (0) b  HT 
2 33  SD followed by WLE and 
SLNB followed by 
mastectomy and breast 
reconstruction 
HG DCIS pTis pN0/i-/M0 
ER: neg PgR: neg Her-2: pos 
44 
          
(0.1posterior) 
 
3 48 9-mm-
large cyst 
on US 
SD followed by WLE and 
SLNB 
IDC G III pT1c pN0/sn/M0 + intraductal 
papilloma 
ER: pos PgR: pos Her-2: neg 
13  
(0.6 posterior) 
WBRT and ChT 
and HT 
4 54 25x15 mm 
mass on 
US 
SD followed by WLE and 
SLNB 
IDC G II extensive DCIS component.pT1b 
pN0/sn/M0 
ER: pos PgR: pos Her-2: neg 
6 (invasive), 48 
(whole)  
(1 posterior) 
WBRT and ChT 
and HT 
5 57  SD followed by WLE and 
SLNB 
LG/IG DCIS pTis pN0/i-/M0 + intraductal 
papilloma 
ER: pos PgR: pos Her-2: neg 
29 (>10) WBRT and HT 
6 66  SD followed by WLE and 
SLNB 
LG DCIS pTis pN0/i-/M0 + intraductal 
papilloma 
ER: pos PgR: pos Her-2: neg 
27 (8) WBRT and HT 
 
 
ChT: chemotherapy; DCIS: ductal carcinoma in situ; ER: estrogen receptor; HER-2: human epidermal growth factor receptor 2; HG: high grade; 
HT: hormonal therapy; IG: intermediate grade; LG: low grade; mm: millimeter; neg: negative; PgR: progesteron receptor; pos: positive; SD: 
selective ductectomy; SLNB: sentinel node biopsy; TNM: Tumor Node Metastases; WBRT: whole breast radiation therapy; WLE: wide local 
excision. 
a  all measures are in mm (closest margin) 
b  reexcision indicated, but patient denying 
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Table 2 Summary of patients with precursor neoplastic lesions 
 
Patient Age Mammography and/or 
ultrasound findings 
Surgery Histology margins Follow-up information 
1 68  SD Papilloma and ADH + CCA 
around 
free, NFS 9 month NED, LFU 
2 61  SD AP, NED around the papilloma free, NFS LFU 
3 50 4-mm-large 
microcalcification  
SD with wire 
localization 
Papilloma and ADH + CCA 
around; microcalcification in 
the papilloma and the CCA 
free, NFS 71 month NED 
4 55 15-mm-large mass with 
microcalcification  
SD with wire 
localization 
AP, NED around the 
papilloma; microcalcification 
in the lesion 
free, 2-3 mm LFU 
5 46  SD AP, NED around the papilloma duct opened,  
possibly 
involved 
43 month NED 
6 66  SD Papilloma and ADH + CCA 
around 
0.3 mm 74 month NED 
7 61  SD AP, NED around the papilloma free, NFS 41 month NED 
8 43  SD with wide 
excision 
Papilloma with radial scar 
associated with ADH around  
not assessable, 
removed in 2 
pieces 
45 month NED 
9 32  SD AP, NED around the papilloma free, NFS LFU 
10 53  SD Papilloma with lobular 
neoplasia outside 
crossing lobular 
neoplasia 
36 month NED 
 
ADH: atypical ductal hyperplasia; AP: atypical papilloma (i.e. papilloma with atypical ductal type hyperplasia within the papilloma); CCA: 
columnar cell alterations encompassing columnar cell changes and hyperplasia without atypia and flat epithelial atypia; LFU: last follow up;  
mm: millimeter; NED: no evidence of disease; NFS: not further specified; SD: selective ductectomy.  
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4.2 Internal mammary sentinel lymph node biopsy in breast cancer. Is it indicated? 
 
A total of 1542 consecutive breast cancer patients with an attempted A-SLNB between 
January 2001 and June 2012 were included in this review. All but 13 patients were women. 
The A-SLNB was successful in 1485 cases, 96% of the patients. At least one A-SLN was 
involved in 606 cases, i.e. 41 % of the patients. Only the data of the 77 patients who had IM-
SLNB were analyzed in details. The histological type of the tumors was as follows: invasive 
carcinoma of no special type (IDC) (n=54), invasive lobular (n=11), mixed ductal and lobular 
(n=2), tubular (n=5), medullary, micropapillary, tubulolobular, metaplastic and mucinous 
carcinoma (n=1 each). The operations performed are summarized in Table 3. 
 
Table 3 Summary of different types of operation in patient with successful IM-SLNB  
 
Characteristic IM-SLN- (n=63) IM-SLN+ 
(n=14) 
Type of the operation   
ROLL+A-SLNB+IM-SLNB 31 5 
ROLL+A-SLNB+ALND+IM-SLNB 5 3 
BCS+A-SLNB+IM-SLNB 21 4 
BCS+A-SLNB+ALND+IM-SLNB 3 0 
Mastectomy+A-SLNB+IM-SLNB 3 1 
Mastectomy+A-SLNB+ALND+IM-
SLNB 
0 1 
 
ALND: axillary lymph node dissection; A-SLNB: axillary sentinel lymph node biopsy; BCS: 
breast conserving surgery; IM-SLN: internal mammary sentinel lymph node IM-SLNB: 
internal mammary sentinel lymph node biopsy; n: number; ROLL: radioguided occult lesion 
localization 
 
IM-SLNs were visualized on preoperative lymphoscintigraphy in 83 of the 1542 
patients (5.4 %), IM-SLNB was successful in 77 cases (93%). Of the 6 failed attempts to 
remove an IM-SLN, the uptake of the SLN was low in one case: although the IM-SLN was 
visualized the day before surgery, it vanished by the next day. The gamma-probe went wrong 
during the operation in a second case. The mean age of patients with successful IM-SLN 
mapping was 56.5 years (range: 33–77). The median tumor size was 14.5 mm. IM-SLNs were 
mostly found in the second or third interspace. This node was typically smaller (0.5–2 mm) 
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than the A-SLN. The IM-SLN stained blue in only 11 patients (14%). A total of 86 IM-SLNs 
were dissected (mean1.1). IM-SLN involvement was identified in 14 cases, which represents 
18% of patients who underwent IM-SLNB. This included macrometastases (MAC) in 5 cases, 
MIC in 2 cases, ITC in 7 cases. In the IM-SLNB group, we removed 114 A-SLNs (average 
1.84). Axillary involvement was found in 16 cases (20 % of the 77 patients) and consisted of 
ITC in 3 cases, MIC in 6 and MAC in 7. No significant differences were found between 
patients with and without IM-SLN involvement in terms of age, tumor location, tumor size, 
axillary involvement, tumor grade or ER status (Table 4). 
 
Table 4 Characteristics of patients with successful IM-SLNB 
Characteristic IM-SLN- (n=63) IM-SLN+ (n=14) P-value 
Age    0.47 
≤50 21 3  
51-70 36 9  
>70 6 2  
Tumor location   0.41 
Lateral 39 7  
Medial or Central 24 7  
Tumor size     
≤20 mm 47 12 0.37 
>20 mm 16 2  
Axillary nodal status    
Negative 49 8 0.41 
Positive 14 4  
Tumor histological grade   0.14 
I 16 6  
II 30 4  
III 17 4  
Estrogen receptor status   0.15 
Negative 8 0  
Positive 55 14  
 
IM-SLN: internal mammary sentinel node; IM-SLNB: internal mammary sentinel node 
biopsy; mm: millimeter; n: number 
In 10 cases (13 % of the IM-SLNB patients) the IM-SLN was involved without A-
SLN involvement. Of these patients, the IM-SLN involvement has lead to new therapeutical 
indications in 2 cases (3% of all IM-SLNB patients), both of them due to MAC in the IM-
SLN. One patient had a change in chemotherapy and one had a change in RT with the 
addition of irradiation of the IMC (Fig. 6). 
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Figure 6 Changes in post-operative adjuvant therapy of patients with IM-SLNB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A-SLN: axillary sentinel lymph node; ChT: chemotherapy; IM-SLN: internal mammary 
sentinel lymph node; IM-SLNB: internal mammary sentinel lymph node biopsy; ITC: isolated 
tumor cells; inv: involvement; MAC: macrometastases; MIC: micrometastases; n: number; 
neg: negative; RT: radiotherapy 
 
A-SLN neg. n=10 
71% 
A-SLN inv. n=4 
29% 
IM-SLN MAC n=3 
30% 
IM-SLN MIC n=1 
10% 
IM-SLN ITC n=6 
60% 
Successful IM-
SLNB n=77 (93%) 
 
IM-SLN inv. n=14 
18% 
IM-SLN neg. n=63 
82% 
New indication in 
ChT n=1 
 
New indication in 
RT n=1 
Attempted IM-
SLNB n=83 
 
Unsuccessful IM-
SLNB n=6 (7%) 
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The patients who had undergone successful IM-SLNB were followed until June 2012, 
their follow-up included AXUS, and no evidence of loco-regional recurrence was noted. 
Median follow-up time was 46 month (range: 2–121 month). Three of the 77 patients in this 
study died, one of distant metastases of breast cancer in the liver, and two of unrelated causes 
(rectal cancer and cardiorespiratory insufficiency). 
IM-SLNB had few complications. Out of the 83 patients in whom IM-SLNB was 
attempted, minor complications were seen in 8 cases (9.6 %). Pleural lesions occurred in 5 
patients (none of them needed thoracic drainage), the injury of the IM artery occurred in 2 
cases and the injury of a minor thoracic vein in 1 case, all three vascular lesions were solved 
by ligation of the respective artery or vein, with no additional incision. There was also one 
major complication (1.2 %): a major retrocostal leak of the IM artery requiring partial 
resection of two adjacent ribs to allow its restauration. The latter patient is well and alive with 
no evidence of disease after 12 months of follow up at the time of writing. 
 
4.3 The role of sentinel node biopsy in male breast cancer. 
 
A total of 25 consecutive MBC patients were included in this review. Sixteen of them 
(64 %) had SLNB. The SLNB was successful in all cases. The remaining 9 patients (36 %) 
had primary ALND. The data of the 25 patients who had SLNB or ALND were analyzed in 
detail. The histological type of the tumors was as follows: IDC (n = 21), invasive lobular (n = 
2), invasive cribriform (n = 1) and mixed invasive micropapillary carcinoma (n = 1). No 
signiﬁcant differences were found between patients with SLNB or ALND in terms of age, 
tumor location, axillary involvement, tumor grade or ER and human epidermal growth factor 
receptor 2 (HER-2) status (Table 5). The only signiﬁcant difference was in tumor size, with 
larger tumors found in the ALND patients. Breast conserving surgery was performed in only 1 
patient. 
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Table 5 Characteristics of male breast cancers  
 
Characteristic ALND group (n=9) SLNB group (n=16) P-value 
Median age (year) 66 64.5 0.6 
Tumor type   0.25 
IDC 8 13  
ILC 1 1  
Other 0 2  
Tumor location   0.92 
Lateral or medial 1 2  
Central 8 14  
Median tumor size (mm) 27 19 0.004 
Axillary nodal status   0.65 
Negative 3 4  
Positive 6 12  
Axillary ultrasound 5 12  
Tumor grade   0.053 
I 1 2  
II 3 11  
III 5 3  
Estrogen receptor status  0  
Positive 7 15 0.24 
Negative 2 1  
HER-2 receptor status   0.17 
Positive 1 0  
Negative 8 16  
 
ALND: axillary lymph node dissection; HER-2: human epidermal growth factor receptor 2; 
IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; mm: millimeter; 
n: number;  SLNB: sentinel lymph node biopsy  
 
4.3.1 Male patients undergoing immediate ALND operation for breast cancer (n = 9) 
 
The average age of the ALND group male patients was 66 years (range 48–82 years). 
All patients underwent mastectomy. Tumor location was central in the majority of patients,  
(n = 8) and lower upper quadrant (n = 1) in the remainder. The primary tumors ranged in size 
from 1.7 to 6 cm (average 2.7 cm). Four of the patients had large tumors: one measuring 4 cm 
and three measuring 6 cm. The axilla was clinically positive in two cases. Preoperative AXUS 
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was used in 5 patients (55 %) and it showed pathologic lymph nodes in 2 cases. There was no 
axillary metastasis in 3 cases (33 %). The therapy used is summarized in Table 6. 
 
Table 6 Summary of treatment of male breast cancers 
 
Characteristic ALND group (n=9) SLNB group (n=16) 
Type of the operation   
Mastectomy+ALND 9 0 
BCS+SLNB+D-ALND 0 1 
Mastectomy+SLNB 0 4 
Mastectomy+SLNB+I-ALND  8 
Mastectomy+SLNB+D-ALND 0 3 
ChT 5 8 
HT 8 15 
WBI 3 3 
WBI+RRT 6 8 
 
ALND: axillary lymph node dissection; BCS: breast conserving surgery; ChT: chemotherapy; 
D-ALND: delayed completion axillary lymph node dissection; HT: hormonal therapy;            
I-ALND: immediate completion axillary lymph node dissection; n:number; SLNB: sentinel 
lymph node biopsy; WBI: whole breast irradiation; RRT: regional radiotherapy 
 
The median follow-up in this group was 5 months (range 1–84). In one case, axillary lymph 
node metastases occurred in the opposite side two years after the initial operation, and 
contralateral ALND was performed. Four patients died due to distant metastases and the 
progression of the disease after one, three, ﬁve and seven postoperative years, respectively. 
 
4.3.2 Male patients undergoing SLNB operation for breast cancer (n = 16) 
 
The average age of the SLNB group male patients was 64.5 years (range 47–76 years). 
Tumor location was central in the majority of patients (n = 14), and lower outer quadrant (n = 
2) in the remainder. The primary tumor ranged in size from 0.6 to 3.5 cm (mean 1.9 cm). All 
patients had a negative axillary status on physical examination. Preoperative AXUS was used 
in 12 patients (75%) and it was negative in all of them. Preoperative lymphoscintigraphy was 
performed in all 16 patients and revealed drainage to the axilla in 15 of them, the axilla and 
the internal mammary region in the remaining 1 case. Intraoperatively, at least one A-SLN 
was identiﬁed in all 16 patients (100% identiﬁcation rate). In one case, we found 4 
macroscopically malignant SLNs by intraoperative palpation and decided for immediate 
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ALND. The mean number of SLNs removed at operation was 1.5 (range 1–5), which is very 
much in keeping with our validation series from the nineties, where the mean number of 
SLNs was 1.3, the accuracy and false-negative rates were 99% and 3%, respectively, with the 
dual labelling method [55]. One IM-SLN and one intramammary SLN were excised during 
the study period. In the patient with the IM-SLN identiﬁed, this lymph node was free of 
metastasis, but the two A-SLNs of the patients were metastatic, one had a MIC and the other a 
MAC. Therefore, ALND was performed and 17 further uninvolved axillary nodes removed.  
In the patient with an intramammary SLN, this node contained a MIC and ALND was 
done with the removal of 23 lymph nodes of which one harboured a MAC. In the SLNB 
group, intraoperative imprint cytology of the SLN was positive in 9 cases and in these we 
performed immediate completion ALND. In the remaining 7 patients, the intraoperative 
imprint cytology was negative. In 3 of them, the ﬁnal histological examination proved SLN 
involvement (none belonged to the MAC category), and delayed completion ALND was 
done. Overall, the sensitivity and speciﬁcity of the intraoperative cytology were 75% (95% 
confidence intervals (CI) 47–91%) and 100% (95% CI 51–100%), respectively. The surgical 
and adjuvant treatments are listed in Table 6. Of the 16 cases with successful SLNB, the SLN 
was involved in 12 patients (75%); 9 patients had MAC, 2 patients had MIC, and 1 patient 
had ITC. In the majority of successful cases, SLNs were identiﬁed by both blue dye and 
isotope (12 cases, 75%).  
In the case of SLN ITC, we could not ﬁnd NSLN involvement. In the MIC group, we 
found NSLN involvement in one of the 2 patients. In the MAC group, NSLN involvement 
was present in 4 of the 9 patients. The lymph node involvement in the ALND and the SLNB 
group of patients with MBC is summarized in Fig. 7. 
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Figure 7 Lymph node involvement in ALND and SLNB group of patients with MBC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALND: axillary lymph node dissection; BC: breast cancer; ITC: isolated tumor cells; inv: 
involvement; MAC: macrometastases; MBC: male breast cancer; MIC: micrometastases; n: 
number; neg: negative; NSLN: non sentinel lymph node; SLN: sentinel lymph node; SLNB: 
sentinel lymph node biopsy 
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4.3.3 Follow-up data 
 
The median follow-up time in the SLNB group was 68 (range:6-137) month. None of 
the patients who underwent SLNB alone had an axillary recurrence during this time. Five of 
the 16 SLNB patients of this study died, one of distant metastases of breast cancer in the lung 
ﬁve years after the operation, and four of unrelated causes (pneumonia and cardiorespiratory 
insufﬁciency 3, 7, 7 and 9 years after the operation, respectively). The median follow-up time 
for all 25 patients was 48 (range: 1–140) months.  
Finally, ALND was performed in 21 patients. Five of these 21 patients had 
lymphedema (24%), appearing after 1 (n = 1), 1.5 (n = 2) and 2 (n = 2) years after the 
operation. In 3 cases, the lymphedema receded signiﬁcantly after one year of physiotherapy. 
A total of 9 patients have died. Out of the surviving 16 patients, 15 have answered a 
postoperative questionnaire about the subjective aspects of the disease. The most interesting 
ﬁnding was that 13 (87%) out of the 15 patients had no previous knowledge of the existence 
of MBC. Two patients had a positive family history: one’s daughter and another’s sister had 
breast cancer. 
The patients were most afraid of surgery and chemotherapy. The 4 patients who had 
undergone SLNB only did not complain of any motoric or sensorial problems on the operated 
side (arm, hand). Nine of the responding patients were in the ALND group. Eight of them 
complained of minor (5) or moderate (3) motoric or sensorial problems on the operated side 
(arm, hand). Twelve of the questioned patients (80%) are seriously worried about a possible 
relapse of the disease and are happy about being under follow-up care having regular check 
ups done. 
 
4.4 Regional disease control in selected patients with sentinel lymph node involvement and 
omission of axillary lymph node dissection. 
 
Between October 2000 and December 2012, 111 patients with demonstrated SLN 
involvement did not undergo an ALND and had at least 12 months of follow-up. The 
characteristics of the patients are summarized in Table 7. 
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Table 7 Basic characteristics of the patients analyzed 
 
Characteristic  
Mean age (year) 60.5 
Mean invasive tumor size (mm) 16 
pT1mic 1 
pT1a 3 
pT1b 15 
pT1c 57 
pT2 32 
pT3 3 
Tumor Grade   
I 21 
II 46 
III 44 
ER-positive 92 
ER-negative 19 
PgR-positive 81 
PgR-negative 30 
HER-2-positive 10 
HER-2-negative 101 
LVI present 19 
LVI absent 92 
SLN ITC 76 
SLN MIC 33 
SLN MAC 2 
 
ER: estrogen receptor; HER-2: human epidermal growth factor receptor 2; ITC: isolated 
tumor cell/cluster; LVI: lymphovascular invasion; MAC: macrometastasis; MIC: 
micrometastasis; mm: millimeter; PgR: progesterone receptor; SLN: sentinel lymph node 
 
 
The majority of the patients had only ITC involvement of the SLNs, but 30% had MIC 
and 2 patients had metastasis larger than 2 mm. All patients undergoing breast conserving 
surgery had adjuvant whole breast irradiation complemented with boost irradiation when the 
margins were close. Axillary RT was given to 29 patients (9 with SLN ITC, 19 with SLN 
MIC and 1 patient with axillary MAC). Systemic therapy involved HT in 75 patients, 
chemotherapy in 13 patients, and their combination in 19 patients. Seven patients with human 
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epidermal growth factor receptor 2 (HER-2) positive tumors also received trastuzumab as part 
of their adjuvant treatment. The median follow-up was 37 months (range: 12-148 months). 
During this period, 6 patients died, 3 of disseminated disease with multiple distant 
metastases (68, 70 and 117 months after surgery, respectively), and 3 of unrelated causes (62, 
90 and 90 months after surgery, respectively). All the 3 patients who died of disease had only 
ITC category SLN involvement. Eight further patients had breast cancer related events: 1 
local breast recurrence in a patient with initial ITC involved SLN, managed surgically with 
repeated SLNB and 2 negative SLNs, and 7 distant metastases (bone 3, lung 1, lung and liver 
with or without bone 2, cerebellum 1). Of the latter patients with distant metastasis, the SLN 
originally harboured ITCs (n=3), MICs (n=3) and MACs (n=1). No axillary regional 
recurrence was detected in any of the 111 patients. The disease free survival (DFS), overall 
survival (OS) and breast cancer specific survival (BCSS) curves based on the Kaplan-Meier 
estimates are shown in Fig. 8.  
The 5-year estimates for DFS, OS and BCSS were 85.7% (standard error, SE: 0.06), 
100% (SE: 0.0) and 100% (SE: 0.0), respectively.  
The nomogram based risks of NSLN involvement in relation to the follow-up events 
are shown in Table 8. 
The nomograms predict for further nodal involvement beyond the SLN, but since there 
were no regional recurrences, local and distant relapses were analyzed in this setting. There 
was no significant difference in the rate of relapse in patients classified as having a high or a 
low risk of NSLN metastasis, independently of the nomogram or predictive tool used. 
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Figure 8 Kaplan-Meier survival curves for the study population 
DFS: Disease free survival; OS: Overall survival; BCSS: Breast cancer specific survival 
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Table 8 Distribution of patients with low volume metastatic SLN involvement according to 
their risk of NSLN metastasis based on the prediction by different predictive tools 
 
Nomogram Low risk (≤10%) High risk (>10%) pa 
French 4-variable nomogram [36]    
NED 53  45  
REC 7 (11.7%) 4 (8.2%) 0.75 
Helsinki nomogram [37]    
NED 67 31  
REC 6 (8.2%) 5 (13.9%) 0.50 
French 5-variable nomogram [38]    
NED 77 21  
REC 7 (9.5%) 4 (16%) 0.45 
Danish risk factors based [35] b     
NED 67 32  
REC 6 (9.0%) 4 (12.5%) 0.73 
 
NED: No evidence of disease; REC: recurrent disease. (Numbers in parentheses reflect the 
percentage of patients who experienced local or distant recurrence of their disease in the given 
risk category.) 
a: Fisher exact test (two-sided); b: low risk defined as 0 or 1 risk factor and high risk defined 
as having >1 risk factors for both MIC and ITC. (For details on risk factors, see Materials and 
Methods).  
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5.  DISCUSSION 
 
5.1 Selective ductectomy for the diagnosis and treatment of intraductal papillary lesions 
presenting with single duct discharge. 
 
Although nipple discharge is a relatively common symptom and is usually benign in 
origin, it can also be a feature of intraductal carcinoma of the breast (DCIS). On the basis of 
previous reports, the incidence of DCIS in patients with nipple discharge varies from 1% to 
16% [60, 61]. Ductography plays an important role in the assessment of single duct discharge, 
because it may visualize intraductal lesions. Although nipple discharge obtained by squeezing 
should be smeared and submitted for cytology in all such cases [62], this approach was not 
very helpful in our hands, as suspicion for malignancy (C4) was not raised in any of the 
patients. In lesions with associated atypia, the cytomorphologic features may overlap with 
those of low-grade IDC, and tissue biopsy might be considered for a definitive diagnosis [63].  
Image-guided needle biopsies are generally the next step to get a diagnosis. Leah at al 
suggest excisional biopsy to be considered when a papillary lesion categorized as B3 is 
identified at percutaneous image-guided breast biopsy [11], because of the probability of 
associated malignancy [58], although these issues are somewhat controversial. Good sampling 
may allow the diagnosis of a benign lesion (B2) as papilloma [58]. Mammary ductoscopy 
(MD) / fiberoptic ductoscopy (FDS) is an endoscopic technique that allows direct 
visualization of the mammary ductal lining using submillimetre fiberoptic microendoscopes 
inserted through the ductal opening onto the nipple surface.  
These scopes also provide working channels for insufflation, irrigation, ductal lavage, 
and possible therapeutic interventions. MD can be performed under local anesthesia in the 
office setting [64]. Although nipple discharge is an unusual presentation for DCIS, FDS with 
ductal lavage cytology can be a useful technique for the diagnosis of DCIS prior to surgery 
[65] in patients with nipple discharge. There was a wide divergence of opinions with regard to 
the treatment of nipple discharge in cases of suspected IP. The various methods of treatment 
included observation with no treatment; infraareolar incision with removal of a small area 
which contains the duct and the intraductal papilloma; wide wedge-shaped incision, removing 
the offending papilloma and several ducts; and a more radical procedure, resection of the 
nipple and areola complex.  
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However, in the last 30 years, a more conservative approach has been accepted, 
stemming mainly from the studies of Haagensen in the United States of America and Atkins 
and Wolff in the United Kingdom [66]. These authors all recognized that patients whose 
discharge was due to IP were cured by the removal of the papilloma. Atkins developed 
microdochectomy through a small cut removal of a single duct following the circular line of 
the areola and Haagensen [7] used a procedure that is between Atkins’ microdochectomy and 
the excision of the major duct performed by Urban [67].  
If the discharge can be localized to a single duct, microdochectomy gives satisfactory 
results in younger patients with minimal or no change of the breast shape and function. SD 
can be considered as a variant of microdochectomy in which the surgeon removes the given 
duct and a small rim of surrounding breast tissue with the guidance of a vital dye (sometimes 
combined with radiocontrast material). MD as a new alternative in the management of 
intraductal proliferations offers the advantages of accurate localization of pathology, ductal 
lavage under direct visualization, and intraoperative guidance especially for lesions deep 
within the ductal system [68].  
In our hospital, the general work-up of single duct discharge through the nipple 
includes mammography, ultrasonography, ductography and discharge cytology. Image guided 
FNAC or CNB are also used for cases with identifiable mass lesions. When these examination 
suggest intraductal proliferations (papillomas in general), SD, a conservative surgical excision 
of limited extent was our method of choice for diagnosing and treating the lesion behind the 
symptom. When malignancy was proven preoperatively, BCS with the ROLL technique or 
mastectomy with SLNB were advocated. In six cases, malignancy was discovered in the 
surgical specimens removed by SD and initiated a second operation in all but one patient who 
had a mastectomy in a third step.  
Breast papillomas may be either solitary or multiple. Solitary papillomas are usually 
found in a subareolar location within the larger ducts, and more than half of the patients 
present with spontaneous nipple discharge. In contrast, multiple papillomas usually arise 
within the terminal duct lobular units and are most frequently peripheral in location. These 
patients rarely present with nipple discharge [69]. Some studies have shown an increased 
potential for malignancy associated with multiple (peripheral) papillomas compared to 
solitary (central) papillomas [7, 70, 71]. The B3 diagnostic category comprises a variety of 
lesions, including papillary lesions which have a lower rate of associated malignancy than the 
B4 (suspicious for malignancy) category, but this rate is still up to 25% [58]. 
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Histopathologically, papillary lesions also comprise a variety of lesions which are classified 
into different diagnostic entities [72].  
Benign papillomas, hyperplastic rather than neoplastic lesions, are characterized by the 
presence of a dual population of luminal epithelial and myoepithelial cells both at the 
periphery and in the papillary areas. These were the most frequent in our series. Papillary 
DCIS is relatively rare in its pure form, but can be admixed with other patterns of DCIS. It is 
characterized by the absence of myoepithelium in the papillary projections, but its presence at 
the periphery of the involved duct. No such lesion was encountered in our study. Invasive 
papillary carcinomas retain the papillary architecture, but have no myoepithelial component.  
There are also specific lesions like the encapsulated papillary carcinoma (also known 
as intracystic or encysted papillary carcinoma) and the solid papillary carcinoma of which the 
real nature is still a matter of debate. They may represent either a form of invasive carcinoma 
with excellent prognosis as would suggest the total or nearly total absence of the peripheral 
myoepithelial layer, and very rare occasions of metastatic disease, but they may also represent 
specific forms of in situ carcinoma as suggested by their indolent clinical behaviour and their 
circumscribed structure suggesting an intraductal origin. Experts tend to classify them on the 
basis of the latter approach [73]. It must also be remembered that papillomas may be 
associated with neoplastic proliferations within the lesions themselves (giving rise to AP or 
papillomas with ADH or frank in situ carcinoma) or around the lesions. Finally, some 
papillary lesions may defeat current categorization guidelines [59]. No encapsulated, solid or 
invasive papillary carcinomas were seen in this series.  
Our data suggest a 6% (95% CI: 3–12%) in situ or invasive malignancy rate for 
patients presenting with simple rather than multiple duct discharge, and a suspicion of 
intraductal proliferation (papilloma) on ductography. For the histopathological entity of IP (77 
in this series), the rate of neoplastic changes was 7.8%, with four overlapping cases having 
both DCIS and IP. Therefore, the clinical presentation we discuss in our series was associated 
with neoplastic epithelial changes in 16 cases (16%): 2 cases without histologically identified 
papillary lesions, and 14 with papillomas (5 fitting in to the frames of atypical hyperplasia in 
the papilloma, 5 with ADH or lobular neoplasia around the papilloma and 4 cases associated 
with DCIS or invasive carcinoma).  
Whether this incidence of malignancy and its predominantly low grade justifies SD for 
the management of single duct discharge raising the possibility of intraductal proliferations 
consistent with central papillomas is a matter of perception. It was felt that the answer to this 
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question was positive, but on the other hand, patients with nothing more than inspissated 
secretion related ductal obliteration and ductectasia as final diagnosis were overtreated. 
Clearly, SD is just one possible approach to manage single duct discharge with papillary 
lesions suspected in the background, and patients should be informed about the pros and cons 
of this minimally invasive intervention, the low rate of malignancy associated with this 
clinical setting and an informed consent should naturally be obtained. Owing to the rather 
uncommon association with malignant findings, a watchful waiting policy could also be a 
viable alternative, although this does not relieve the leading symptom of nipple discharge. 
Whether surgery is needed for a disease or a symptom associated with such a low 
incidence of malignancy, can be questionable. However, after meeting the patients, it became 
clear, that nipple discharge can be very unpleasant and this minimal diagnostical operation 
promptly cease the symptom. Considering the possibility of the oncological overtreatment 
(93% of the patients had no malignant lesion, and the importance of the five in situ 
carcinomas is unclear) it is very important to inform the patients about the magnitude of the 
risk of malignancy.  
Some authors make the diagnosis with CNB, others with vacuum assisted biopsy. The 
treatment of these B3 risk lesions is contradictional, there are authors who suggest a surgical 
excision [11, 74], and others do not find this necessary, only in the case of papillary lesions 
[75]. The indication for the operations in this series was very similar, although the diagnosis 
of IP was not established by using CNB, but was raised with high suspicion with ductography 
performed for single duct discharge after previous mammographic and US examinations. 
After informing the patients about the alternatives, one option can be ductoscopy, but 
this is not available in some countries, including Hungary. Biopsy of the papillary lesion, if it 
can be visualized by mammography or US is the most followed option, but there were only 
four such visible lesion among our cases. Another alternative can be the radiological follow 
up. 
 
5.2 Internal mammary sentinel lymph node biopsy in breast cancer. Is it indicated? 
 
The SLN is the first lymph node to receive lymphatic drainage from a tumor, and 
SLNB is a minimally invasive diagnostic modality for diagnosing axillary lymph node 
metastases in breast cancer. Many studies on lymphatic drainage of the breast have confirmed 
the importance of the IM basin as a second draining route in breast cancer [76, 77]. As a 
consequence, IMC lymph node dissection (IMC-LND) was part of the standard surgical 
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treatment in some centers in the 1950s and 1960s. This radical surgical procedure was 
abandoned in the 1970s because patient outcome studies showed that radical dissection did 
not improve survival [1]. However, these studies have clearly shown that patients with 
documented IM metastases, who did not receive adjuvant therapy, had a worse prognosis [1]. 
Veronesi et al. found in their analysis of 1119 patients that survival was significantly affected 
by the presence of positive IMC nodes. Ten-year survival varied between 80 % in patients 
with axillary and IMC negative nodes, 55 % in axillary positive and IMC negative nodes, 53 
% in IMC positive and axillary negative patients and 30 % in patients with both axillary and 
IMC positive nodes [78].  
Since the introduction of SLNB, there has been a renewed interest in the IM-SLNs. As 
a consequence, IM-SLNB can refine staging in breast cancer patients and offers the 
possibility of providing tailored treatment in case of proven metastases to the IMC. Some 
authors have found a correlation between the location of the tumor and the visualized IM-
SLN. The proportion of patients in whom the IM-SLN could be visualized was found to be 
higher in patients with a tumor in the medial or central part of the breast, compared to those 
with a tumor in the lateral part of the breast [1, 19, 78]. 
Other authors have not found such an association [79, 80]. In keeping with the 
unpredictability of lymphatic drainage on the basis of tumor location, this series demonstrated 
IM drainage in more lateral tumors than medial or central tumors. The higher rate of IM 
drainage in medial tumors may reflect their lower overall frequency compared to lateral 
tumors. The rate of identification of SLNs in the IM region is lower than in the case of A-
SLNB [22]. The success rate of A-SLNB in the literature is between 94–97%, compared to 
the success rate of 63–88 % of IM-SLNB [1, 78, 80]. There are two main reasons for this. 
Firstly, IM-SLNB is not performed routinely, as opposed to A-SLNB, because many breast 
surgeons have concerns about the rate of complications of the procedure, due to the lack of 
technical expertise and familiarity with the route of access.  
Secondly, it is difficult to compare the results of the different studies. US-guided intra- 
or peritumoral tracer administration followed by lymphoscintigraphy (draining via the 
perforating lymphatic system) has a higher rate of IMC drainage than subareolar or subdermal 
injections using the superficial lymphatic system [81]. It may also be hypothesized that a 
peritumoral injection more accurately demonstrates the true lymphatic drainage of the tumor 
than an injection given away from the tumor site in the skin or around the areola [81], despite 
the fact that most of the time the breast can be and is viewed as a single organ with a unique 
drainage independently of tumor location [82]. 
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Because of these issues, the reported rates of IMC drainage on lymphoscintigraphy 
vary greatly, from <2% to 38% of all breast tumors [83]. The proportion of patients with IMC 
drainage reported here (5.4%) is also an underestimate of all patients with this phenomenon, 
because the universal intraparenchymal radiotracer administration used in the first part of the 
study period was replaced by the use of this administration route only for non-palpable tumors 
having a smaller chance of nodal involvement. This caveat should be kept in mind, but the 
data did not allow a better approach of the rate of IMC drainage, and the study concentrated 
more on the IM-SLNB and its implications in patients with a visualized drainage to this 
region, rather than the drainage itself.  
In our series the success rate of A-SLNB was 96% and that of IM-SLNB was 93%. 
The latter high rate may be a consequence of the fact that the procedure was first introduced 
by a breast and thoracic surgeon (Gábor Boross), and most operations were performed by 
experienced breast surgeons.  
The number of axillary nodes involved is also an important prognostic information 
[84] and this may hold true for the number of metastatic IMC lymph nodes too. The overall 
risk of IM-SLN metastasis in breast cancer patients is well known and reported to be 18–33%. 
Metastases exclusively situated in the IM node, without concurrent axillary metastases, occur 
in 2–11% of patients [85]. A larger axillary metastatic load may represent a higher risk of 
IMC metastasis [1], and the total number of involved nodes in the two regions together may 
likewise be important from a prognostic aspect, but this is currently very difficult to assess, as 
IMC-LND is not part of the standard treatment of breast carcinoma [22]. In our study, no 
significant differences were found between patients with and without IM-SLN involvement in 
terms of age, tumor location, tumor size, axillary involvement, tumor grade or ER status.  
A possible role of nodal positivity detected by IM-SLNB may be the indication of 
more aggressive systemic treatment in axillary node-positive patients. Adjuvant locoregional 
RT has proven to be beneficial after mastectomy [86–88], but the contribution of radiation to 
the IMC to improve survival and recurrence rates is still unclear [89–92]. Although RT of the 
parasternal region does not seem to improve the survival [93], the value of this treatment in 
IM-SLN-positive patients detected by IM-SLNB should also be assessed in future studies 
[22].  
The EORTC 22922/10925 trial has been devised to investigate the potential survival 
benefit and toxicity of elective irradiation of the internal mammary and medial 
supraclavicular (IM-MS) nodes. It is currently evaluating the impact of IM-MS irradiation on 
long term disease-free and overall survival in breast cancer patients with centrally or medially 
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located tumors. Only lung (fibrosis; dyspnoea; pneumonitis; any lung toxicities) but not 
cardiac toxicity increased significantly with IM-MS treatment. IM-MS irradiation seems well 
tolerated and does not significantly impair performance status at 3 years. A follow-up period 
of at least 10 years is needed to determine whether cardiac toxicity is increased after such 
radiotherapy [94]. As for today, there is insufficient data to determine a positive effect of 
parasternal RT on survival in patients with proven IM metastases.  
Axillary adjuvant RT is beneficial in terms of locoregional control in high-risk 
subgroups, such as patients with more than 3 axillary metastases [94]. As a consequence, by 
extrapolation, it could be reasonable to add parasternal RT to the treatment regimen in 
patients with tumor-positive IM-SLNs, if their metastatic volume is higher, e.g. in case of 
MAC or multiple nodal involvement. In contrast to adjuvant RT to the IMC, systemic 
treatment of high-risk breast cancer patients has a proven survival benefit [95]. Its 
administration is based on a set of prognostic and predictive factors, of which nodal status is 
only one, even if considered among the most important ones.  
The systemic treatment strategy was rarely influenced by IM metastases in this series 
of patients. Due to axillary metastases and unfavourable primary tumor characteristics, a lot of 
patients would have already received adjuvant chemotherapy and even more of them would 
have had adjuvant HT. In the remaining patients, old age and negative ER status further 
limited the proportion of patients who would have received adjuvant systemic therapy based 
on IM-SLN metastases. Dutch national guidelines on the treatment of breast cancer do not 
recommend routine biopsy of the IM-SLNs. 
Adjuvant chemotherapeutic treatment and IMC irradiation is however indicated when 
a tumor-positive IMC lymph node is found [96]. IM-SLNB may be associated with some 
additional morbidity in about 3–10 % of the cases, according to the literature: pleural lesions 
or injury of the IM artery [1, 19, 78]. Recovery is usually uneventful in the case of pleural 
lesions, after simple vacuum drainage. The injury of the IM artery poses more serious 
challenges. In our study we recognized minor complications in 8 cases (9.6%) and one major 
complication (1.2%) also occurred. Recovery was uneventful in both the minor and the major 
complication group. The literature is rather inconclusive as concerns the recommendation of 
IM-SLNB. Table 9 shows details and main conclusions of larger IM-SLNB studies. 
On the basis of recent publications, arguments for performing IM-SLNB are the 
following: 
It helps the correct staging of patients with breast cancer [22]. IM-SLN involvement is 
a prognostic factor [22] and an adverse prognostic indicator of increased distant metastases 
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and reduced survival, even in the absence of axillary disease [78]. In case of IM-SLN-positive 
patients, the treatment can be altered (chemo- or radiotherapy) [22]. Studies evaluating the 
effect of the IM-SLNB on the treatment strategy in patients with an IMC drainage pattern 
report a change of treatment in 2–9 % [94, 100]. Since adjuvant systemic treatment in this 
small but substantial patient group is likely to improve prognosis, authors of these studies 
recommend routine biopsy of IM-SLNs. 
There are also arguments against IM-SLNB, and these are listed as follows: 
IM-SLN metastases occur only in a small proportion of patients undergoing SLNB 
(1.4–4.6 %) [22, 100], (although they have a higher rate of occurrence (18–33%) [55] in 
patients having IMC drainage and IM-SLNB. US-guided intra- or peritumoral tracer 
administration demonstrates a higher rate of IMC drainage than subareolar or subdermal 
injections which are often used for A-SLNB. Overall, isolated IM-SLN involvement is rare 
(2–9 %) [22, 94, 100]. If the A-SLNs are negative, then IM-SLNs are also negative in 41.2%–
56.6% [22]. Although there could be new indications for IMC RT if both A-SLNs and IM-
SLNs are positive (13.2–22.7%) [22] and for chemotherapy if A-SLNs are negative but an 
IM-SLN is positive (2.1–9%), the IM node status resulted in a change of the adjuvant 
treatment plans in only 3.4 % of the patients [1]. 
Some authors have found predictive factors of IMC positivity, including age<35 years, 
grade III histology and lymphatic vascular invasion [78], that would make IM-SLNB less 
important.  
The impact of IM-SLNB on altering adjuvant systemic therapy was relatively small in 
our series. We have found IM-SLN involvement in 14 cases, which represents 18% of the 
patients who underwent IM-SLNB, but in 7 cases, only ITC were found, and these are not 
considered metastasis at present [101]. Neither ITC, nor MIC nor MAC of the IM-SLN has 
lead to further surgical therapy. Micrometastases in A-SLNs or IM-SLNs were not an 
indication for adjuvant chemotherapy. 
In our series, only 1 patient received RT to the IMC, and a new indication for 
chemotherapy was also established in only 1 patient because of MAC of the IM-SLN. 
Therefore in our series consisting of 77 patients, only 2 of the IM-SLNB patients (2.6 %) had 
therapeutic consequences. As for today, there are insufficient data to determine a positive 
effect of parasternal RT on survival in patients with proven IM metastases. On the other hand, 
IM-SLNB may be associated with some additional morbidity: pleural lesions or injury of the 
IM artery.  
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Table 9 Details and main conclusions of larger IM-SLNB studies 
 
 
IM: Internal mammary; IMC: internal mammary chain; IM-SLN: internal mammary sentinel lymph node; IM-SLNB: internal mammary sentinel 
lymph node biopsy; LVI: lymphovascular invasion; RT: radiotherapy; SLN: sentinel lymph node; SLNB: sentinel lymph node biopsy 
Reference Number 
of 
patients 
IM hot 
nodes % 
Number 
of IM-
SLNB 
patients 
% of IM 
metastases 
% of IM 
metastases 
without 
axillary 
metastases 
Predictors of 
IMC positivity 
Opinion 
Nathan J (78) 577 18 90 22 18 age<35 
Grade 3 
LVI 
IM-SLNB allows for improved staging, potential 
improvements in regional control, and the potential 
to increase long term survival and the identification 
of patients who may benefit from IMC radiation. 
E.M Heuts (1) 1008 20 139 22 29 tumor location Patients with IM hotspots have a substantial 
risk (22%) of IM-SLN metastases. True IM 
node negative patients can be spared the 
morbidity associated with adjuvant RT. 
E.V.E Madsen 
(80) 
499 17 85 24 1 axillary 
metastases 
 IM-SLNB is recommended when SLNs are 
visualized by preoperative 
lymphoscintigraphy. 
E.M Heuts (97) 764 22 115 24 25  Routine IM-SLNB is recommended and treatment of 
proven IM metastases should be done according to 
its results. 
E.L  Postma 
(98) 
493 24 107 13 7  Since the adjustment rate of systemic treatment 
based on the finding of this procedure is minimal 
and there is no sufficient ground for adjustment of 
RT, IM-SLNB should not be performed routinely. 
M.H.K 
Leidenius (99) 
984 14 138 13 2  IM-SLNB results in upstaging in 2% of all breast 
cancer patients who undergo SLNB. The clinical 
value of the procedure seems insignificant, although 
it may influence the adjuvant treatment regimen in 
some patients. 
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5.3 The role of sentinel node biopsy in male breast cancer 
 
Because of the lack and uselessness of general screening in this sex, MBC is rarely 
detected mammographically. It mostly manifests as a palpable mass, at a later stage and a 
larger tumor size. The majority of MBC patients undergo mastectomy because of the small 
breast size and subareolar location of most malignancies [102]. Because of the low incidence, 
treatment for breast cancer in men has been extrapolated from the experience of treatment of 
breast cancer in women, without the beneﬁts of randomized trials. ALND is associated with a 
number of complications, including lymphedema, axillary paresthesia and decreased range of 
motion of the shoulder and arm. SLNB permits removal of a smaller number of lymph nodes 
that can be subjected to a more detailed pathologic examination, resulting in improved staging 
of the regional lymph nodes [103]. Randomized trials have also demonstrated decreased 
morbidity with SLNB compared to ALND, and SLNB has rapidly been incorporated into the 
treatment of women with early-stage breast cancer [104-110].  
The ﬁrst SLNB in MBC was reported in 1999 by Hill and colleagues [46] from the 
Memorial Sloan-Kettering Cancer Center. Since that report, its use has increased and there are 
several additional studies reporting on 6, 9, 16, and 18 patients [45, 47-49]. Since the 
experience was published in 2004, SLNB has been routinely offered to all male patients with 
breast cancer and clinically negative axillary nodes, according to the standard policy applied 
to women with breast cancer at the European Institute of Oncology, Milan, Italy [48]. 
Frequently, breast cancer in men is diagnosed at an advanced stage, making SLNB 
inappropriate, but still a considerable proportion of patients present with a clinically negative 
axilla, therefore making them candidates for a less invasive method of axillary staging. At the 
beginning of the study period, mastectomy was performed with immediate ALND, without 
attempting SLNB. The reasoning behind this policy was as follows: the size of tumors in 
males is typically larger compared to females, larger tumors are more often accompanied by 
lymph node metastases, and there were insufﬁcient data on the role of SLNB in male patients. 
This approach was used in 9 patients.  
The ﬁnal histological examination of the ALND specimen proved a negative nodal 
status in 3 of them. One of these cases was seen in 2004, at the beginning of the examined 
period, before the accumulation of sufﬁcient evidence allowing SLNB in MBC. The second 
patient was 82 years old, and the avoidance of a possible second axillary operation in case of 
a metastatic SLN arguably deviated us from SLNB. The last patient had a 4-cm-large tumor 
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and had a strong clinical suspicion of axillary metastases. In our experience, 4 of 16 patients 
(25%) who underwent SLNB were spared an unnecessary axillary dissection. Should SLNB 
been performed in all male patients with negative axillae, 3 further men could have been 
spared the potential morbidity of ALND, and this rate could have been 7/25. As shown in 
Table 5, the group treated with upfront ALND was not very much different from the one 
where SLNB was attempted, except for tumor size and the 2 cases where the axilla was 
clinically positive.  
The SLNB procedure is a technically feasible and accurate method of evaluating males 
with clinically node-negative BC [47, 111]. If an SLN is positive for metastatic disease, 
complete ALND has been recommended [112]. Owing to the relatively high rate of nodal 
involvement, intraoperative SLN examinations are of value. The sensitivity of imprint 
cytology found in our small series does not seem very gratifying, but is in line with the 63% 
(95% CI 57–69%) pooled sensitivity of the method reported by a meta-analysis [113], and if 
only MACs are considered, the sensitivity goes up to an idealistic 100%. Although the choice 
of intraoperative assessment should be based on local preferences and expertise [114], frozen 
sections seem somewhat better than imprint cytology [115], but both methods become worse 
with MICs. Quantitative molecular methods like one step nucleic acid ampliﬁcation are 
probably the most sensitive methods, if one wants to detect virtually all metastases [116]. 
Table 10 shows details and main results of larger SLNB studies relating to MBC. 
Our experience is in keeping with the data summarized in Table 10. 
Compared to female patients, a larger proportion of male patients (75%) have positive 
nodes, but for patients with clinically negative nodes, SLNB may reduce morbidities 
associated with ALND. 
The feed-back from the patients in our questionnaire shows that in the SLNB group 
patients had no motoric and sensory problems as opposed to the ALND group where a large 
majority complained about these, and this supports the idea that SLNB is associated with less 
morbidity than ALND in male patients too. A panel of the American Society of Clinical 
Oncology stated that ‘‘although the data are limited… it is unlikely that SLNB will be any 
less accurate in men than it is in women’’ [118]. The cumulative evidence from previously 
published and the current series support this notion. In the absence of stronger evidences 
based on larger numbers, it seems reasonable to recommend modiﬁed radical mastectomy as 
the gold standard in men, in whom an SLN cannot be identiﬁed.  
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Reference Number of 
patients 
SLNB 
successful % 
SLNB 
positive % 
Median 
age (year) 
Palpable 
mass % 
Mean 
tumor size 
(cm) 
Tumor 
histology 
(IDC) % 
ER positive 
% 
Mastectomy 
% 
Flynn L.W 
(117) 
78 97 49 60 77 1.9 83 98 ni 
Rusby J.E 
(118) 
31 96 61 62 42 1.9 84 100 81 
Boughey J.C 
(111) 
30 100 37 62.5 80 2 83 97 100 
Gentilini O      . 
(119) 
32 100 19 58  <1 in 70% 71 100 100 
Our results 16 100 75 61 78 1,9 81 94 94 
Table 10 Summary of literature on male sentinel node biopsy in breast cancer 
cm: centimeter; ER: estrogen receptor; IDC: invasive ductus carcinoma; ni: no information; SLNB: sentinel lymph node biopsy 
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5.4 Regional disease control in selected patients with sentinel lymph node involvement and 
omission of axillary lymph node dissection. 
 
Lymph node status is still considered one of the most powerful prognostic factors in 
breast cancer. Besides being a qualitative prognosticator (metastatic lymph nodes or a positive 
nodal status versus the lack of metastases, i.e. a negative nodal status) it is also a quantitative 
one. A greater tumor burden in the regional lymph nodes reflects worse prognosis, and 
conversely, a smaller tumor burden means smaller and even questionable disadvantage in 
prognosis.  
The involvement of NSLNs is influenced by several factors among which the size / 
degree of the SLN involvement is one of the most important. Low-volume SLN metastases of 
the micrometastatic category are associated with NSLN positivity in 10-15% of the cases 
[120], a proportion which is confirmed by the data of recent clinical trials [27-29], but as 
highlighted in the introduction, depending on the combination of several factors, this may 
double or triple in a minority of patients [35-38]. In this respect, ITCs do not seem much 
better, as on average, they are suggested to be associated with NSLN involvement in about 
12% of the cases according to a meta-analysis [121].  
It must also be remembered that until recently, the distinction between ITC and MIC 
by pathologists was far from perfect [122, 123]. Taking all this together, analyzing patients 
with SLN MIC or ITC together makes sense. Although current trends favor the omission of 
ALND in many patients with minimal SLN involvement including all with SLN MIC [37, 
38], this approach may ignore a small minority of patients who could potentially benefit from 
further axillary treatment [35, 124]. This makes follow-up studies of patients with involved 
SLNs but no ALND important. 
One of the first studies of the kind reported no axillary recurrence for a selected group 
of SLN micrometastatic patients with favorable prognostic profile during a median follow-up 
period matching the present one [125]. Likewise, this series also included mainly patients 
deemed to have a low risk of further nodal involvement, including many with SLN ITC only. 
Unlike in other studies, some patients with omitted ALND and receiving RT to the breast 
following breast conservation, also got irradiation of the axillary region, which we believe to 
constitute an overtreatment in patients with low risk of axillary NSLN involvement. In 
keeping with the results of the first similar report [125], no axillary recurrence occurred 
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during the follow-up period, but 11 breast cancer related events were noted, including 3 
deaths from metastatic disease.  
The results of clinical trials looking at the safety of omitting ALND in patients with 
minimal SLN involvement [27-29], also point to a very low rate of axillary recurrence after a 
somewhat longer median follow-up, and the occurrence of local (in breast) and systemic 
disease recurrence. This seems unrelated to the manifestation of recurring axillary cancer 
(Table 11), and also to the predicted risk of NSLN involvement on the basis of predictive 
tools devised for low volume SLN metastasis patients (Table 8).  
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Table 11 Follow-up events of patients with SLN involvement and no ALND in published reports 
 
 
 
 
Study, 1st author Patients MAC/MIC/ITC 
Median follow-up 
(months) 
Axillary 
recurrence 
Breast 
recurrence Metastasis DOD DOOC 
Meretoja TJ 
[125] 48 0/22/26 37 0 1 2 1 9 
Present 111 2/33/76 37 0 1 10 3 3 
Galimberti V[29] 467 0/467/0 60 5 8 25 0 2 
Sola [28] 116 0/116/0 62 2 0 1 0 0 
Giuliano AE [27] 359 160/199/ni 75 4 8 ni ni ni 
 
 
DOD: dead of disease, DOOC: dead of other (unrelated) causes, ITC: isolated tumor cell/cluster, MAC: macrometastasis, MIC: micrometastasis, 
ni: no information. (Studies listed according to length of median follow-up.) 
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6. CONCLUSIONS 
6.1 
Single duct nipple discharge with  ductographic findings suggestive of intraductal 
proliferation was associated with malignancy (most of the time in situ carcinoma) in 6% of 
the cases and atypical hyperplasia in further 10% of the cases. For such a low risk and 
generally low grade of malignancy, simple follow-up could be offered from a surgical and an 
oncological point of view, but in some cases, considering the patients’ request to get rid of the 
symptoms, SD could be applied. Whenever associated mass lesions or microcalcifications are 
identified, these require separate work-up, including non-operative guided biopsies or surgical 
excisions for both high risk lesions on non-operative diagnostics and lesions with 
inconclusive non-operative assessment. Our retrospective analysis suggests that SD is well 
tolerated, has no major complications and might be a realistic diagnostic and therapeutic 
approach in the clinical situations described above. 
6.2 
Based on our own series and information from the literature, we conclude that the 
indication for an IM-SLNB procedure is very limited, and its routine use should not be 
recommended — which is also in agreement with the latest Hungarian guidelines [126]. A 
failure to identify an A-SLN is an indication for ALND in general, but it is felt that if there is 
no lymphatic drainage towards the axilla on lymphoscintigraphy, and even vital dye guided 
A-SLNB fails to identify an A-SLN, but an IM-SLN is visualized on the lymphoscintigram, 
IM-SLNB could be considered for nodal staging, and the omission of ALND could also be 
envisaged. In the studied setting, the data point more to abandoning routine IM-SLNB in 
patients with IMC drainage and potentially restricting its use to a very small subset of 
patients. 
6.3 
We conclude that SLN operations in male patients with clinically node-negative BC 
are feasible and accurate and appear to be an appropriate alternative to routine ALND. 
Intraoperative evaluation of the SLN should be strongly considered in the surgical 
management of MBC patients. 
6.4 
The presented retrospective data suggest that omitting ALND in patients with low 
volume SLN metastasis may be a safe procedure, and support the observation that systemic 
disease recurrence may not be associated with axillary recurrence or the risk of NSLN 
involvement predicted by nomograms.  
52 
 
7. ACKNOWLEDGEMENTS  
I thank  
- my supervisor, Dr Gábor Cserni, Professor at the Department of Pathology, University of 
Szeged and head of the Department of Pathology, Bács-Kiskun County Teaching Hospital, 
Kecskemét for his time, support and the scientific guidance of my work; 
- Dr. Mihály Svébis, principal director of Bács-Kiskun County Teaching Hospital, for his 
support of my work; 
- the general support of Drs József Pap-Szekeres and Gábor Pajkos, heads of the 
Departments of Surgery and Oncology at the Bács-Kiskun County Teaching Hospital, 
respectively for providing me excellent conditions to carry out the presented works; 
- the help of Gábor Fejes, Department of Informatics; 
- Drs. Gábor Boross, László Markó, Éva Ambrózay, Mária Rajtár, Gabriella Gábor, 
Rita Bori, Csaba Polgár and Aida Sirbu, Tünde Gyapjas, Józsefné Ritka, Andrea 
Domokos, Zsolt Kárpáti who also helped this thesis to be born;  
at last, but not least, my family for encouraging and supporting me. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
8. REFERENCES 
 
1. Heuts EM, van der Ent FW, Hulsewe KWE et al. Internal mammary lymph drainage and sentinel                               
node biopsy in breast cancer - A study on 1008 patients. Eur J Surg Oncol 2009; 35:252–257.  
2. Tabár L, Duffy SW, Neuman HB. The natural history of breast carcinoma: what have we learned 
from screening? Cancer 1999; 86: 449-462. 
3. Cady B, Stone MD, Schuler JG et al. The new era in breast cancer. Invasion, size, and nodal 
involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996; 131: 
301-308. 
4. Cserni G. The sentinel lymph node theory in breast cancer. (Az őrszemnyirokcsomók elmélete 
emlőrákban) Magyar Tudomány 2004; 7: 718-722. (Hungarian)  
5. Greif F, Sharon E, Shechtman I et al. Carcinoma within solitary ductal papilloma of the breast. 
EJSO 2010; 36:384–386.  
6. Maxwell AJ. Ultrasound guided vacuum-assisted excision of breast papillomas: review of 6-years 
experience. Clin Radiol 2009; 64:801–806.  
7. Haagensen CD. Diseases of the Breast, 3rd ed, Solitary intraductal papilloma. Philadelphia: WB 
Saunders. 1986; pp 137–175  
8. Hou MF, Huang TJ, Liu GC. The diagnostic value of galactography in patients with nipple 
discharge. Clin Imaging 2005; 25:74–81.  
9. Bruce L, Daniel R, Gardner W et al. Magnetic resonance imaging of intraductal papilloma of the 
breast. Mag Reson Im 2003; 21:887–892.  
10. Hünerbein M, Dubowy A, Raubach M et al. Gradient index ductoscopy and intraductal biopsy of 
intraductal breast lesions. Am J Surg 2007; 194:511–514.  
11. Leah S, Feldman SM, Balassanian R et al. Association of breast cancer with papillary lesions 
identified at percutaneous image-guided breast biopsy. Am J Surg 2004; 188:365–370. 
12. Veronesi U, Viale G, Paganelli G et al. Sentinel lymph node biopsy in breast cancer: ten-year 
results of a randomized controlled study. Ann Surg 2010; 251:595-600.  
13. Zavagno G, De Salvo GL, Scalco G et al. A randomized clinical trial on sentinel lymph node 
biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM Trial. 
Ann Surg 2008; 247: 207–213.  
14. Andersson Y, de Boniface J, Jönsson PE et al. Axillary recurrence rate 5 years after negative 
sentinel node biopsy for breast cancer. Br J Surg 2012; 99: 226-231.  
15. Hunt KK, Ballman KV, McCall LM et al. Factors associated with local-regional recurrence after a 
negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg 2012; 256:428-436.  
16. Krag DN, Anderson SJ, Julian TB et al. Sentinel-lymph-node resection compared with 
conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: 
overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11:927-
933. 
17. Uren RF, Howman-Giles RB, Thompson JF et al. Mammary lymphoscintigraphy in breast cancer. 
J Nucl Med 1995; 36:1775–1780.  
18. Lamonica D, Edge SB, Hurd T et al (2003) Mammographic and clinical predictors of drainage 
patterns in breast lymphoscintigrams obtained during sentinel node procedures. Clin Nucl Med 2003; 
28:558–564.  
19. Van der Ent FW, Kengen RA, van der Pol HA et al. Halsted revisited: internal mammary sentinel 
lymph node biopsy in breast cancer. Ann Surg 2001; 234:79–84.  
20. Estourgie SH, Nieweg OE, Valdes Olmos RA et al. Lymphatic drainage patterns from the breast. 
Ann Surg 2004; 239:232–237.  
21. Estourgie SH, Tanis PJ, Nieweg OE et al. Should the hunt for internal mammary chain sentinel 
nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol 2003; 10:935–941.  
54 
22. Cserni G, Pap-Szekeres J. Internal mammary lymph nodes and sentinel node biopsy in breast 
cancer. Surg Oncol 2001; 10: 25–33. 
23. Veronesi U, Cascinelli N, Bufalino R et al. Risk of internal mammary lymph node metastases and 
its relevance on prognosis of breast cancer patients. Ann Surg 1983; 198: 681-684. 
24. Cserni G, Burzykowski T, Vinh-Hung V et al. Axillary sentinel node and tumorrelated factors 
associated with non-sentinel node involvement in breast cancer. Jpn J Clin Oncol 2004; 34:519-524. 
25. Viale G, Maiorano E, Pruneri G et al. Predicting the risk for additional axillary metastases in 
patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005; 241:319-325. 
26. Veronesi U, Viale G, Paganelli G et al. Sentinel lymph node biopsy in breast cancer: ten-year 
results of a randomized controlled study. Ann Surg 2010; 251:595-600. 
27. Giuliano AE, McCall L, Beitsch P et al. Locoregional recurrence after sentinel lymph node 
dissection with or without axillary dissection in patients with sentinel lymph node metastases: the 
American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 252:426-
432. 
28. Solá M, Alberro JA, Fraile M et al. Complete axillary lymph node dissection versus clinical 
follow-up in breast cancer patients with sentinel node micrometastasis: final results from the 
multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol 2013; 20:120-127. 
29. Galimberti V, Cole BF, Zurrida S et al. Axillary dissection versus no axillary dissection in patients 
with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet 
Oncol 2013; 14:297-305. 
30. Park J, Fey JV, Naik AM et al. A declining rate of completion axillary dissection in sentinel lymph 
node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg 
2007; 245:462-468. 
31. Bilimoria KY, Bentrem DJ, Hansen NM et al. Comparison of sentinel lymph node biopsy alone 
and completion axillary lymph node dissection for node-positive breast cancer. J. Clin. Oncol 2009; 
27:2946-2953. 
32. Wasif N, Maggard MA, Ko CY et al. Underuse of axillary dissection for the management of 
sentinel node micrometastases in breast cancer. Arch Surg 2010; 145:161-166. 
33. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes – dealing with the diversity of 
breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of 
Early Breast Cancer 2011. Ann Oncol 2011; 22:1736-1747. 
34. AGO, DGS, SGS, ÖGS, Panelists, Executive Board Members. German, Austrian and Swiss 
consensus conference on the diagnosis and local treatment of the axilla in breast cancer. Eur J Cancer 
2013; 49:2277-2283. 
35. Tvedskov TF, Jensen MB, Lisse IM et al. High risk of non-sentinel node metastases in a group of 
breast cancer patients with micrometastases in the sentinel node. Int J Cancer 2012; 131:2367-2375. 
36. Meretoja TJ, Strien L, Heikkilä PS et al. A simple nomogram to evaluate the risk of non-sentinel 
node metastases in breast cancer patients with minimal sentinel node involvement. Ann Surg Oncol 
2012; 19:567-576. 
37. Houvenaeghel G, Nos C, Giard S et al. A nomogram predictive of non-sentinel lymph node 
involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol 
2009; 35:690-695. 
38. Houvenaeghel G, Bannier M, Nos C et al. Non sentinel node involvement prediction for sentinel 
node micrometastases in breast cancer: nomogram validation and comparison with other models. 
Breast 2012; 21:204-209. 
39. Grabau D, Dihge L, Ferno M et al. Completion axillary dissection can safely be omitted in screen 
detected breast cancer patients with micrometastases. A decade’s experience from a single institution. 
EJSO 2013; 39:601-607. 
40. Crichlow RW, Galt SW. Male breast cancer. Surg Clin N Am. 1990;70:1165–1177. 
41. Donegan WL, Redlich PN. Breast cancer in men. Surg Clin N Am. 1996;76:343–363. 
42. Fentiman IS, Fourquet A, Hortobagyi G. Male breast cancer. Lancet. 2006; 367:595–604. 
55 
43. Gennari R, Curigliano G, Jereczec-Fossa Bet al. Male breast cancer: a special therapeutic problem. 
Anything new? Int J Oncol 2004; 24: 663–670. 
44. Albo D, Ames FC, Hunt KK et al. Evaluation of lymph node status in male breast cancer patients: 
a role for sentinel lymph node biopsy. Breast Cancer Res Treat. 2003;77:9–14. 
45. Port ER, Fey JV, Cody HS 3rd et al. Sentinel lymph node biopsy in patients with male breast 
carcinoma. Cancer 2001; 91:319–323. 
46. Hill AD, Borgen PI, Cody HS 3rd. Sentinel node biopsy in male breast cancer. Eur J Surg Oncol 
1999; 25:442–443. 
47. Cimmino VM, Degnim AC, Sabel MS et al. Efﬁcacy of sentinel lymph node biopsy in male breast 
cancer. J Surg Oncol 2004; 86:74–77. 
48. De Cicco C, Baio SM, Veronesi P et al. Sentinel node biopsy in male breast cancer. Nucl Med 
Commun. 2004; 25:139–143. 
49. Goyal A, Horgan K, Kissin M et al. ALMANAC Trialists Group, et al. Sentinel lymph node 
biopsy in male breast cancer patients. Eur J Surg Oncol 2004; 30: 480–483. 
50. Kuenen-Boumeester V, Menke-Pluymers M, de Kanter AY et al. Ultrasound-guided fine needle 
aspiration cytology of axillary lymph nodes in breast cancer patients. A preoperative staging 
procedure. Eur J Cancer 2003; 39:170–174. 
51. Sapino A, Cassoni P, Zanon E et al. Ultrasonographically guided fine-needle aspiration of axillary 
lymph nodes: role in breast cancer management. Br J Cancer 2003; 88:702–706. 
52. Ambrózay E, Cserni G, Serényi P et al. The role of axillary nodal staging during preoperative 
breast diagnostics. Eur J Cancer Suppl 2004; 2:92–93 
53. Gennari R, Galimberti V, De Cicco C et al. Use of technetium 99m-labeled colloid albumin for 
preoperative and intraoperative localization of non palpable breast lesions. J Am Coll Surg 2000; 
90:692–699. 
54. Cserni G. Complete sectioning of axillary sentinel nodes in patients with breast cancer. Analysis of 
two different step sectioning and immunohistochemistry protocols in 246 patients. J Clin Pathol 2002; 
55:926–931. 
55. Greene FL, Page DL, Fleming ID et al. (eds) AJCC Cancer Staging Handbook New York. 
Springer, Berlin, 2002; p 469 
56. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137:678–
687. 
57. Ottini L, Palli D, Rizzo S et al. Male breast cancer. Crit Rev Oncol Hematol. 2010;73:141–155. 
58. Amendoeira I, Apostolikas N, Bellocq JP et al. Quality assurance guidelines for pathology. In: 
Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds) European guidelines for 
quality assurance in breast cancer screening and diagnosis, 4th edn. European Commission, 
Luxemburg 2006; pp 219–311. 
59. Cserni G. Benign apocrine papillary lesions of the breast lacking or virtually lacking myoepihelial 
cells- potential pitfalls in diagnosing malignancy. APMIS 2012; 120:249–252. 
60. Leis HP Jr. Management of nipple discharge. World J Surg 1989; 13:736–742. 
61. Buhl-Jorgensen SE, Fischermann K, Johansen H et al. Cancer risk in intraductal papilloma and 
papillomatosis. Surg Gynecol Obstet 1968; 127:1307–1312. 
62. Al Sarakbi W, Worku D, Escobar PF et al. Breast papillomas: current management with a focus on 
a new diagnostic and therapeutic modality. International Seminars in Surgical Oncology 2006; 3:1. 
63. Sneige N. Fine-needle aspiration cytology of in situ epithelial cell proliferation in the breast. Am J 
Clin Pathol 2000; 113:38–48. 
64. Kefah M, Pedro FE, Tadaharu M. Mammary ductoscopy: current status and future prospects. 
EJSO 2005; 31:3–8. 
65. Shen K-W, Wu J, Lu J-S et al. Fiberoptic ductoscopy for breast cancer patients with nipple 
discharge. Surg Endosc 2001; 15:1340–1345. 
66. Atkins H, Wolff B. Discharge from the nipple. BJS 1964; 51:602–606. 
67. Urban JA. Excision of the major duct system of the breast. Cancer 1963; 16:516–520. 
56 
68. Dietz JR, Crowe JP, Grundfest S et al. Directed duct excision by using mammary ductoscopy in 
patients with pathologic nipple discharge. Surgery 2002; 132:582–587. 
69. Cardenosa G, Eklund GW. Benign papillary neoplasms of the breast: mammographic findings. 
Radiology 1991; 181:751–755. 
70. Ali-Fehmi R, Carolin K, Wallis T et al. Clinicopathologic analysis of breast lesions associated 
with multiple papillomas. Hum Pathol 2003; 34:234–239. 
71. Page DL, Salhany KE, Jensen RA et al. Subsequent breast carcinoma risk after biopsy with atypia 
in a breast papilloma. Cancer 1996; 78:258–266. 
72. O’Malley F, Visscher D, MacGrogan G et al. Intraductal papillary lesions. In: Lakhani SR, Ellis 
IO, Schnitt SJ et al (eds) WHO classification of tumors of the breast, 4th edn. International Agency for 
Research on Cancer, Lyon, 2012; pp 99–109. 
73. Cserni G. The current TNM classification of breast carcinomas: controversial issues in early breast 
cancer. memo Magazine of European Medical Oncology 2011; 4:144–148. 
74. Sakr R, Rouzier R, Salem C et al. Risk of breast cancer associated with papilloma. EJSO 2008; 
34:1304–1308. 
75. El-Sayed ME, Rakha EA, Reed J et al. Predictive value of needle core biopsy diagnoses of lesions 
of uncertain malignant potential (B+) in abnormalities detected by mammographic screening. 
Hystopathology 2008; 53:650–657. 
76. Hultborn KA, Larsson LG, Ragnhult I. The lymph drainage from the breast to the axillary and 
parasternal lymph nodes, studied with the aid of colloidal AU198. Acta Radiol 1955; 43:52–64. 
77. Turner-Warwick RT. The lymphatics of the breast. Br J Surg 1959; 46:574–582. 
78. Nathan J, Boyages J, French JR et al. Internal mammary sentinel nodes: ignore, irradiate or 
operate? Eur J Cancer 2008; 45:789–794. 
79. Veronesi U, Cascinelli N, Greco M et al. Prognosis of breast cancer patients after mastectomy and 
dissection of internal mammary nodes. Ann Surg 1985; 202:702–707. 
80. Madsen E, Gobardhan PD, Bongers V et al. The impact on post-surgical treatment of sentinel 
lymph node biopsy of internal mammary lymph nodes in patients with breast cancer. Ann Surg Oncol 
2007; 14:1486–1492. 
81. Roumen RMH, Geuskens LM, Valkenburg JGH et al. In search of the true sentinel node by 
different injection techniques in breast cancer patients. Eur J Surg Oncol 1999; 25:347–351. 
82. Borgstein PJ, Meijer S, Pijpers RJ et al. Functional lymphatic anatomy for sentinel node biopsy in 
breast cancer: echoes from the past and the periareolar blue method. Ann Surg 2000; 1: 81–89. 
83. Spillane AJ, Noush IF, Cooper RA et al. High resolution lymphoscintigraphy is essential for 
recognition of the significance of internal mammary nodes in breast cancer. Ann Oncol 2009; 20:977–
984. 
84. Sugg SL, Ferguson DJ, Posner MC et al. Should internal mammary nodes be sampled in the 
sentinel lymph node era? Ann Surg Oncol 2000; 7:188–192 
85. Van der Ent FW, Kengen RA, van der Pol HA et al. Halsted revisited: internal mammary sentinel 
lymph node biopsy in breast cancer. Ann Surg 2001; 234:79–84. 
86. Overgaard M, Jensen MB, Overgaard J et al. Postoperative radiotherapy in high-risk 
postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative 
Group DBCG 82c randomised trial. Lancet 1999; 353:1641–1648. 
87. Ragaz J, Jackson SM, Le N et al. Adjuvant radiotherapy and chemotherapy in node-positive 
premenopausal women with breast cancer. N Engl J Med 1997; 337:956–962. 
88. Whelan TJ, Julian J, Wright J et al. Does locoregional radiation therapy improve survival in breast 
cancer? A meta-analysis. J Clin Oncol 2000; 18:1220–1229. 
89. Obedian E, Hafty BG. Internal mammary nodal irradiation in conservatively managed breast 
cancer patients: is there a benefit? Int J Radiat Oncol Biol Phys 1999; 44: 997–1003. 
90. Freedman GM, Fowble BL, Nicolaou N et al. Should internal mammary lymph nodes in breast 
cancer be the target for the radiation oncologist? Int J Radiat Oncol Biol Phys 46:805–814. 
91. Jatoi I. Internal mammary sentinel nodes in primary breast cancer. Curr Med Res Opin 2003; 
19:567–569. 
57 
92. Fowble B, Hanlon A, Freedman G et al. Internal mammary node irradiation neither decreases 
distant metastases nor improves survival in stage I and II breast cancer. Int J Radiat Oncol Biol Phys 
2000; 47:883–894. 
93. Matzinger O, Heimsoth I, Poortmans P et al. Toxicity at three years with and without irradiation of 
the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer 
(EORTC trial 22922/10925) Act. Oncol 2010; 49:24–34. 
94. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of 
surgery for early breast cancer on local recurrence and 15-year survival: an overview of the 
randomised trials. Lancet 2005; 366: 2087–2106. 
95. Early Breast Cancer Trialists’ Collaborative Group (EBCTGC) Effects of chemotherapy and 
hormonal therapy for early breast cancer: effects on recurrence and 15-year survival: an overview of 
the randomised trials. Lancet 2005; 365:1687–1717. 
96. Dutch national guideline for the treatment of breast cancer, version 2.0 (Feb2012) 
http://www.oncoline.nl/mammacarcinoom. Accessed 22 Feb 2012 
97. Heuts EM, van der Ent FW, Hulsewe KWE et al. Results of tailored treatment for breast cancer 
patients with internal mammary lymph node metastases. The Breast 2009; 18:254–258. 
98. Postma EL, van Wieringen S, Hobbelink MG et al. Sentinel lymph node biopsy of the internal 
mammary chain in breast cancer. Breast Cancer Res Treat 2012; 134:735–774. 
99. Leidenius MHK, Krogerud LA, Toivonen TS et al. The clinical value of parasternal sentinel node 
biopsy in breast cancer. Ann Surg Oncol 2006; 13: 321–326. 
100. Coombs NJ, Boyages J, French JR et al. Internal mammary sentinel nodes: ignore, irradiate or 
operate? Eur J Cancer 2009; 45:789–794. 
101. Cserni G. What is a positive sentinel lymph node in a breast cancer patient? A practical approach. 
Breast 2007; 16:152–160 
102. Kiluk JV, Lee MC, Park CK et al. Male breast cancer: management and follow-up 
recommendations. Breast J 2011; 17:503–509. 
103. Giuliano AE, Dale PS, Turner RR et al. Improved axillary staging of breast cancer with sentinel 
lymphadenectomy. Ann Surg 1995; 222:394–399 (discussion 399–401). 
104. Luci A, Mackie L, Beitsch PD et al. Surgical complications associated with sentinel lymph node 
dissection (SLND) plus axillary lymph node dissection, versus SLND alone in The American College 
of Surgeons Oncology Group (ACOSOG) Trial Z0011. Ann Surg Oncol 2006; 13 [2 Suppl]:4. 22.  
105. Peintinger F, Reitsamer R, Stranzl H et al. Comparison of quality of life and arm complaints after 
axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer 
2003; 89:648–652.  
106. Schijven MP, Vingerhoets AJ, Rutten HJ et al. Comparison of morbidity between axillary lymph 
node dissection and sentinel node biopsy. Eur J Surg Oncol 2003; 29:341–350.  
107. Golshan M, Martin WJ, Dowlatshahi K. Sentinel lymph node biopsy lowers the rate of 
lymphedema when compared with standard axillary lymph node dissection. Am Surg 2003; 69: 209–
211 (discussion 212).  
108. Schrenk P, Rieger R, Shamiyeh A et al. Morbidity following sentinel lymph node biopsy versus 
axillary lymph node dissection for patients with breast carcinoma. Cancer 2000; 88: 608–614.  
109. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with 
routine axillary dissection in breast cancer. N Engl J Med 2003; 349:546–53.  
110. Fleissig A, Fallowﬁeld LJ, Langridge CI et al. Post-operative arm morbidity and quality of life. 
Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary 
treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006; 
95:279–293. 
111. Boughey JC, Bedrosian I, Meric-Bernstam F et al. Comparative analysis of sentinel lymph node 
operation in male and female breast cancer patients. J Am Coll Surg 2006; 203:475–80. 
112. Lyman GH, Giuliano AE, Somerﬁeld MR et al. American Society of Clinical Oncology guideline 
recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 
7703–7720.  
58 
113. Tew K, Irwiq L, Matthews A et al. Meta-analysis of sentinel node imprint cytology in breast 
cancer. Br J Surg 2005; 92:1068–1080. 
114. Cserni G, Amendoeira I, Apostolikas N et al. Pathological workup of sentinel lymph nodes in 
breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer 
2003; 39:1654–1667.  
115. Liu LC, Lang JE, Lu Y et al. Intraoperative frozen section analysis of sentinel lymph nodes in 
breast cancer patients. Cancer 2011; 117:250–258.  
116. Cserni G. Intraoperative analysis of sentinel lymph nodes in breast cancer by one-step nucleic 
acid ampliﬁcation (OSNA). J Clin Pathol 2012; 65:193–199. 
117. Flynn LW, Park J, Patil SM et al. Sentinel lymph node biopsy is successful and accurate in male 
breast carcinoma. J Am Coll Surg 2008; 206:616–621.  
118. Rusby JE, Smith BL, Dominguez FJ et al. Sentinel lymph node biopsy in men breast cancer: a 
report of 31 consecutive procedures and review of the literature. Clin Breast Cancer 2006; 7:406–410.  
119. Gentilini O, Chagas E, Zurrida S et al. Sentinel lymph node biopsy in male patients with early 
breast cancer. Oncologist 2007; 12:512–515. 
120. Cserni G, Gregori D, Merletti F et al. Meta-analysis of non-sentinel node metastases associated 
with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004; 91:1245-1252. 
121. van Deurzen CH, de Boer M, Monninkhof EM et al. Non-sentinel lymph node metastases 
associated with isolated breast cancer cells in the sentinel node. J Natl Cancer Inst 2008;100:1574-
1580. 
122. De Mascarel I, MacGrogan G, Debled M et al. Distinction between isolated tumor cells and 
micrometastases in breast cancer: is it reliable and useful? Cancer 2008; 112:1672-1678. 
123. Cserni G, Bianchi S, Vezzosi V et al. Variations in sentinel node isolated tumor cells / 
micrometastasis and non-sentinel node involvement rates according to different interpretations of the 
TNM definitions. Eur J Cancer 2008; 44:2185-2191. 
124. Cserni G, Bezsenyi I, Marko L. Patients' choice on axillary lymph node dissection following 
sentinel lymph node micrometastasis--first report on prospective use of a nomogram in very low risk 
patients. Pathol Oncol Res 2013; 19: 211-216. 
125. Meretoja TJ, Vironen JH, Heikkila PS et al. Outcome of selected breast cancer patients with 
micrometastasis or isolated tumor cells in sentinel node biopsy and no completion axillary lymph node 
dissection. J Surg Oncol 2010; 102: 215-219. 
126. Lázár G, Besznyák I, Boross G et al (2010) Az emlőrák korszerű sebészi kezelése. M Onkol 
2010; 54:227–236. 
 
59 
9. APPENDIX 
  
 
 
 
I. 
  
 
 
 
 
 
II. 
  
 
 
 
 
 
III. 
  
 
 
 
 
 
IV. 
 
